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ABSTRACT 
Multiple myeloma remains an incurable hematological malignancy due to the failure of 
standard-of-care therapies to broadly target a genetically heterogeneous disease and an inability 
overcome inevitable drug-resistant relapse. This dissertation will address this outstanding 
problem through two approaches: transcriptomic profiling to predict resistance to proteasome 
inhibitors and pre-clinical evaluation of epigenetic-targeting therapies to broadly target the 
myeloma epigenome. 
First, our goal was to develop a gene expression signature that predicts response 
specific to proteasome inhibitor (PI) treatment in MM. Using a well-characterized panel of human 
myeloma cell lines (HMCLs) representing the biological and genetic heterogeneity of MM, we 
created an in vitro chemosensitivity profile in response to treatment with the four PIs as single-
agents. Through gene expression profiling and machine learning-based computational 
approaches we identified a 42-gene expression signature that could not only distinguish good and 
poor PI-response in the HMCL panel, but could also be successfully applied to four different 
clinical datasets on MM patients undergoing PI-based chemotherapy to distinguish between 
extraordinary (good and poor) outcomes. Our results demonstrate the use of in vitro modeling 
and machine learning-based approaches to establish predictive biomarkers of response and 
resistance to drugs that may serve to better direct myeloma patient treatment options. 
Epigenetic abnormalities are abundantly present in multiple myeloma and accumulating 
evidence suggests that the histone methyltransferase EZH2 is aberrantly active in MM. We tested 
the efficacy of EZH2 specific inhibitors in a large panel of human MM cell lines (HMCLs) and 
found that only a subset of HMCLs demonstrate single agent sensitivity despite ubiquitous global 
H3K27 demethylation. Pre-treatment with EZH2 inhibitors greatly enhanced the sensitivity of 
HMCLs to the pan-HDAC inhibitor panobinostat in nearly all cases regardless of single agent 
EZH2 inhibitor sensitivity. Transcriptomic profiling revealed large-scale transcriptomic alteration 
by EZH2 inhibition highly enriched for cancer-related pathways. Further analysis demonstrated 
that combination treatment further perturbed oncogenic pathways and signaling nodes consistent 
with an antiproliferative/pro-apoptotic state. We conclude that combined inhibition of HDAC and 
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EZH2 inhibitors is a promising therapeutic strategy to broadly target the epigenetic landscape of 
aggressive MM. 
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CHAPTER 1  
INTRODUCTION 
1.1 - Multiple Myeloma: Overview and History 
Multiple Myeloma (MM) is a devastating hematologic cancer that remains largely 
incurable despite progressive advancements in disease management over the last several 
decades [1]. MM is the second most common hematologic cancer in the United States that has 
over 30,000 new cases each year and accounts for about two percent of all cancer deaths [2,3]. 
MM has a higher incidence among males and is primarily a disease of the elderly with a median 
age at diagnosis of roughly 70 years [3]. 
While MM has arguably been present for centuries [4], the first reports of MM date back 
to the late 19th century where ovular cells bearing prominent nuclei were observes in patients 
with “soft bones” [5]. It was later observed that these patients had an unusual urinary proteins that 
were then referred to as Bence Jones proteins named after their discoverer [6]. Today we know 
Bence Jones proteins as the immunoglobulin light chains produced by overabundant antibody-
producing plasma cells [7]. The quantification of these overabundant paraproteins, known as an 
“M-spike”, is still used today to diagnose and monitor MM through all stages of the disease [8,9]. 
The term “multiple myeloma” first appeared in J.V. Rustizky’s 1873 description of eight bone 
tumors identified in one post-mortem patient [10]. However, it was not until 1900 that the above 
characteristics were fully appreciated to embody our current understanding of MM [11].  
Today MM is defined as a lymphoid neoplasm characterized by clonal expansion of 
malignant post-germinal-center B-cell-derived plasma cells within the bone marrow compartment 
[2]. Clinically, this disease is characterized by several well-characterized symptoms [12]. The 
increasing burden of antibody-producing plasma cells in the bone marrow elevates serum Ig 
levels, which can directly lead to renal impairment/failure [13]. The presence of osteolytic bone 
lesions in MM is caused by an aberrant increase in osteoclast activity and a concomitant 
decrease in osteoblast activity induced through interaction with MM cells [14,15]. Bone resorption 
leads to the release of calcium into circulation leading to hypercalcemia [16]. Immunodeficiency is 
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also a common symptom of MM and in late stages of the disease the inability to combat 
additional illnesses can be the fatal attribute [12].  
 
1.2 - Myeloma Biology: Lymphoid Differentiation, Myeloma Etiology and Stages of Disease 
 MM is a disease characterized by the malignant proliferation of antibody-producing 
plasma cells in the bone marrow. Understanding the biological origins of MM is predicated on an 
understanding of how plasma cells develop from their lymphoid progenitors. The human immune 
system is a constantly changing network of diverse cell types that coordinate to recognize foreign 
antigens and target them for removal from the host. Producing cells that express receptors and 
antibodies that are conjugated specifically to foreign antigens is a complicated developmental 
process that tightly regulates a balance between positive and negative selection. This persistent 
state of proliferation and selection throughout lymphoid development can, over time, present a 
myriad of opportunities for the acquisition of genetic aberrations. Under the right conditions these 
aberrations can lead to undue proliferation and result in the development of one of many 
lymphoid neoplasms distinguished by their genetic/epigenetic landscape and stage of lymphoid 
differentiation.  
1.2.1 – Lymphoid Differentiation and the Origins of Lymphoid Neoplasms 
The developmental path towards a malignant plasma cell (Figure 1) begins in the bone 
marrow with a multi-potent lymphoid progenitor stem cell population [17–20].  Commitment to the 
lymphoid lineage can produce several essential effectors of the immune system (B, T and natural 
killer cells) that progress through subsequent stages of maturation to produce and enhance 
antigen specificity [21]. The developmental process of establishing and refining B cell antigen 
specificity is achieved through the controlled multi-step rearrangement of the genomic loci 
encoding immunoglobulin chains [22]. Rearrangements of these loci will produce genes that 
encode peptides with unique antigen binding regions that can then be further altered (e.g. 
mutations) and selected for specificity. While these genomic modifications are generally restricted 
to specific loci, aberrant modifications can occur on other genes at several stages. 
  
3 
 
Figure 1: MM etiology and progression within the stages lymphoid differentiation 
 A simplified schematic of B-cell development and the initiation/progression of MM. Linear 
differentiation of the B-cell lineage from a common lymphoid progenitor to the terminal 
developmental stage: long-lived plasma cells expressing high-affinity antibodies. Aberrant 
genomic lesions (i.e. mutations and translocations) are produced during clonal 
expansion/selection in the germinal center via somatic hypermutation and class-switch 
recombination errors. These lesions may persist in long-lived plasma cells that return to the bone 
marrow microenvironment, elevating their proliferative capacity. Continued growth permits 
acquisition of additional oncogenic lesions that results in a progressive increase in monoclonal 
plasma cell burden in the bone marrow and a concomitant increase in serum Ig. Accumulation of 
genomic lesions promotes branching sub-clonal diversification and competition for the bone 
marrow micro-environment progressively selects more aggressive growth. Pre-malignant phases 
of disease (smoldering MM and MGUS) precede presentation of disease symptoms that 
characterize fully malignant MM. The terminal developmental stage of disease, plasma cell 
leukemia, is characterized by bone-marrow-independent growth in the host.   
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The process of establishing antigen specificity within the B cell linage begins with the pro-
B cell stage of development [22]. Pro-B cells undergo recombination between the variable (V), 
diversity (D) and joining (J) regions of the immunoglobulin heavy chain locus (IgH) [23]. 
Completion of this process, termed V(D)J recombination, and the subsequent expression of Pax5 
defines commitment to the B-cell lineage. Expression of the successfully recombined heavy chain 
in concert with a surrogate light chain forms the  
pre-B-cell-receptor (pre-BCR) complex. Pre-BCR establishment halts additional IgH 
recombination and promotes allelic exclusion to restrict pre-BCR complexes to the recognition of 
a single potential antigen.  
 The next stage of B cell development, the pre-B cell stage, initiates recombination of the 
Ig light chain locus. Similar to IgH V(D)J recombination in the previous stage, the light chain 
undergoes recombination between V and J regions. Successful rearrangement and expression of 
the light chain complexes with the heavy chain to produce IgM. Expression of IgM at the cell 
surface signifies the successful transition into the immature B cell. Immature B cells undergo 
selection where cells that recognize self-antigens and cannot persist outside the bone marrow 
microenvironment are negatively selected [24].  
Positive selection for bone-marrow independence allows immature B cells to leave the 
bone marrow and become mature (naïve) B cells distinguished by cell surface expression of both 
IgM and IgD. Mature B cells enter the follicles of the spleen and lymph nodes as follicular B cells 
where they can become activated [22]. T-cell-independent activation of follicular B cells via 
exposure to antigen drives differentiation into short-lived plasma cells that secrete low affinity 
antibodies as part of a short lived immune response. Antigen activation of follicular B cells 
facilitated by T cells drives follicular B cells into the germinal center (GC) where they undergo 
further affinity maturation as part of establishing a long-term immune response [22]. 
Many opportunities for oncogenesis are present during the stages of genomic 
modification in B cell differentiation stages preceding activation of follicular B cells. Genomic 
lesions established during these stages can eventually manifest as MM, however, this can also 
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represent the origin for other lymphoid neoplasms including acute lymphoblastic leukemia, 
chronic lymphocytic leukemia, mantle cell lymphoma and mantle zone lymphoma [17]. 
In the GC, follicular B cells transition into GC B cells which undergo expansion and 
selection aimed at increasing antigen affinity [22]. GC B cells express the mutagenic enzyme 
activated-induced cytidine deaminase (AID) that is targeted to the V region of the heavy chain. At 
that locus AID mutagenesis increases diversity to allow further selection for enhanced antigen 
specificity in a process called somatic hyper mutation (SHM). Following SHM and matured 
specification AID also directs isotype switching from IgM to IgG or IgA. This process is referred to 
as class-switch recombination (CSR).  
In the normal, non-pathogenic progression of the lymphoid lineage (i.e. sans aberrant 
genomic lesions) GC B cells that have high-affinity B cell receptors survive negative selection and 
are resigned to two fates as they exit the GC environment. A minority population of these GC B 
cells become long-lived non-secretory B-cells that are responsible for maintaining long-term 
recognition of antigens by the host immune system [25]. The remaining majority of these post-GC 
B cells differentiate into plasmablasts. Plasmablasts are an intermediate stage of differentiation 
between GC B cells and terminally differentiated plasma cells [26,27]. They initially maintain their 
highly proliferative GC behavior driven in part by BCL-6/PAX-5 repression of the plasma cell 
genes XBP-1 and BLIMP-1. Gradually, these intermediate plasmablasts begin adopting a 
transcriptomic profile consistent with mature plasma cells by elevating expression of IRF4 and 
NF-κB. This in turn represses BCL-6 and PAX-5 while enhancing Ig secretion, morphological 
changes and expression of XBP-1/BLIMP-1 [28]. BLIMP-1 in particular is considered a master 
regulator of plasma cell differentiation and its expression allows plasma cells to leave the lymph 
nodes and return to the bone marrow as long-lived plasma cells [29]. These terminally 
differentiated lymphoid cells reside in the bone marrow as non-dividing, Ig-secreting facilitators of 
the sustained immune response to foreign antigens [30].   
1.2.2 – Multiple Myeloma: Pre-malignant Stages and Disease Progression 
As outlined above, establishing and selecting for high affinity immunoglobulins is an 
essential process for the adaptive immune system. However, accomplishing robust 
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receptor/antibody diversity requires several stages of precise genomic modification, which, when 
executed erroneously, can set the stage for oncogenic transformation. As with V(D)J 
recombination, SHM and CSR present additional opportunities for aberrant genomic modification. 
The specific context of these aberrations and the stage at which they result in uncontrolled growth 
distinguishes several lymphoid malignancies that can arise from SHM and CSR. Follicular 
lymphoma, Burkitt lymphoma and diffuse large B cell lymphoma are thought to originate directly 
from GC B cells while Waldenström's macroglobulinemia and MM are thought to be derived from 
the post-GC B cell lineage [17]. With respect to MM, evidence has accumulated to implicate 
founding aberrations that have SHM/CSR signatures (e.g. IgH translocations at the switch locus) 
while the clonal nature of malignant plasma cell Ig’s indicates a post-GC (post-affinity 
maturation/selection) origin [31–34]. This suggests that while the founding genetic events that 
result in MM occur in developmental stages well upstream of terminal differentiation. 
MM originates from long-lived plasma cells residing in the bone marrow, however, 
malignant transformation is not an immediate consequence of terminal differentiation for cells 
harboring genomic lesions as discussed above. Rather, MM is thought to develop gradually the a 
series of pre-malignant stages that have specific clinical definitions [1]. Monoclonal gammopathy 
of undetermined significance (MGUS) is present in about 1% of adults over the age of 25 and has 
a roughly 1% chance per year of advancing to MM [35–37]. MGUS is diagnosed/monitored via 
serum Ig levels, lacks symptoms of end-organ damage associated with MM and is defined by a 
clonal bone marrow plasma cell burden below 10% [9]. MGUS often goes undiagnosed prior to 
progression in MM and the value of treating the disorder in light of low risk for progression 
remains an ongoing debate. Smoldering MM similarly lacks symptoms of end-organ damage and 
has a bone marrow plasma cell burden below 10%. Smoldering MM is distinct from MGUS in that 
is presents a higher serum monoclonal protein levels (≥3gm/dL) and has a much higher risk of 
progression to MM (~10% per year) [9,38]. Malignancy and the designation of MM is finally 
established as symptoms of end-organ damage (described above) appear and the plasma cell 
burden in the bone marrow exceeds 10% [1]. MM continues to persist in the bone marrow, 
however once bone marrow independence occurs and malignant plasma cells proliferate in the 
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peripheral blood, the disease has progressed to the exceptionally aggressive terminal stage: 
plasma cell leukemia [39].  
The etiology of MM is established during the complex progression of B-cell development 
where a great diversity of founding genetic aberrations can be acquired and maintained through 
terminal differentiation. These diverse origins result in a diverse and complex disease that is 
equally diverse and complex in patients. 
 
1.3 - The Genetic Landscape of Myeloma 
  MM is a highly heterogeneous disease. As described above, MM is distinct from other 
GC-based malignancies in that founding genetic lesions are not sufficient to dive malignant 
transformation but rather several additional abnormalities must be acquired after terminal 
differentiation. The genomic landscape of MM varies greatly from patient to patient due, in part, to 
the diverse set of initial genomic abnormalities that establish pre-malignancy. This heterogeneity 
is further exacerbated by genomic instability that continues throughout disease progression and 
persistent competition for the bone marrow microenvironment that maintains branching sub-clonal 
evolution within any individual case of MM [40,41].  
The advent of several modern sequencing technologies and their application to large 
cohort studies has provided a large body of knowledge regarding the clonal and sub-clonal 
heterogeneity present in MM [40,42–48]. A great many genomic abnormalities have been 
identified in MM (Table 1). Among them, several have notable reoccurrence. Dissecting the 
wealth of genomic data available from numerous cases of MM reveals some genomic lesions that 
display clear characteristics of being founding events while others seem to more frequently 
accumulate during disease progression with less clear contribution. This dichotomy between early 
and late genomic lesions is more commonly referred to as ‘driver’ and ‘passenger’ events where 
drivers initiate/facilitate malignant proliferation and passengers accumulate due to persistent 
genomic instability. Characterizing all of the many reoccurring genetic abnormalities provides 
invaluable insights towards understanding the biology underlying MM’s ability to progress and 
evade therapy.  
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1.3.1 – Chromosomal Abnormalities 
 Chromosomal abnormalities are a classic hallmark of MM genomics. Such chromosomal 
abnormalities generally fall into two categories: hyperdiploidy found in 50% of patients and 
translocations on chromosome 14 with the IgH locus found in 45% of patients (distinguished as 
hyperdiploid or non-hyperdiploid MM) [49]. 10% bear both types and only 5% of patients have 
neither [49]. Acquisition of either of these abnormalities is considered a founding or initiating 
event in MM and their diverse effects on disease biology can have prognostic implications for 
therapy [49]. 
 In non-hyperdiploid MM IgH translocations arise from either V(D)J recombination or 
SHM/CSR where double stranded DNA breaks at the IgH locus (Chr. 14q32) are aberrantly 
repaired through recombination with distant loci. The IgH gene is expressed after a strong 
promotor. When this promotor is translocated in front of a proto-oncogene, expression of that 
gene can be enhanced well beyond its normal level. The most common IgH translocations in MM 
all act in this way. In some cases this rapidly promotes malignant transformation as with IgH-MYC 
translocations observed in Burkitt lymphoma [50]. In MM, however, IgH translocations do not 
promote full transformation until after terminal differentiation and the acquisition of additional 
abnormalities (‘second hits’).  
Common IgH translocations in MM include  t(4;14), t(6;14), t(11;14), t(14;16) and 
t(12;20). In many of these cases cyclin D proteins are over expressed, promoting undue 
progression through the G1-S checkpoint of cell cycle regulation [51]. The most common 
translocation, t(11;14), occurs between 14q32 and 11q13 (in 15-20% of patients) and drives over 
expression of CCND1 (cyclin D1). Other cyclin D overexpressing translocations include 
t(6;14)(q21:q32)(cyclin D3) and t(12;14)(cyclin D2). Translocations t(14;16) and t(14;20) indirectly 
upregulate cyclin D2 by directly overexpressing c-MAF and MAFB respectively.  
Other common translocations also drive expression of non-cyclin proteins. Translocation t(4;14), 
an indicator of poor prognosis, overexpresses MMSET (an epigenetic regulator discussed in 
more detail below) and FGFR3 (a receptor tyrosine kinase). Translocation t(6;14)(p25;q32) 
overexpresses IRF4 (a transcription factor significant for plasma cell differentiation).  
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Table 1: The most frequent genomic abnormalities observed in myeloma  
Type of Genomic Lesion Genomic Lesion(s) 
Notable Genes or 
Processes 
Affected 
MM 
Frequency 
or Notes 
Primary 
Founding 
Events 
IgH 
Translocations 
(Non-
hyperdiploid): 
50% of MM 
cases [48] 
t(4;14) MMSET & FGFR3  
t(6;14)(q21;q32) CCND3  
t(6;14)(p25;q32) IRF4  
t(11;14) CCND1 15-20%  
t(14;16) c-MAF  
t(12;20) MAFB  
t(12;14) CCND2  
Hyperdiploidy: 
45% of MM 
cases [48] 
Gain of odd numbered 
chromosomes: 
3,5,7,9,11,15,19,21 
 Better 
prognosis 
than non-
hyperdiploid 
Secondary 
Events 
Secondary 
translocations 
[48] 
Translocations between MYC 
and strong promotors (e.g. 
IGH,IGL,IGK, FAM46C, 
FOXO3 or BMP6) 
MYC More 
prevalent in 
late-stage 
disease 
Common copy 
number 
variations 
 
 [48] 
Large gain of chromosome  
regions: 1q, 3, 5, 6p, 7, 9, 11q, 
15, 18, 19, 21 
 
 
Large loss of regions on 
chromosomes: 1q, 6p, 8,12, 
13,14,16, 17p, 20 and 22 
1q loss (30% of 
cases) removes 
FAM46C, CDKN2C 
and FAF1 
17p loss 
removes 
TP53 in 
aggressive 
MM 
Focal Gain: 1q22, 2p14, 
3p24.3, 3q26.2, 
5q35.2,6p24.3, 7q22.1, 
8q24.2, 9q34.13, 11q13.2, 
12q34.21, 15q24.2, 17q23.2, 
19p13.2, 20q11.22 and 
22q13.1 
1q22 minimally 
contains 679 genes 
including CKS1B 
and ANP23E 
 
Focal loss: 1p21.3, 4p15.31, 
4q13.1, 6q25.3, 7q11.22, 
8p22, 9p24.1, 10q24.33, 
12p13.1, 12q21.33, 13q21.33, 
14q32.32 and 16p13.3 
  
Most frequent 
somatic 
mutations  
 
[40,42,52] 
KRAS RAS/MAPK pathway 20-21% 
NRAS RAS/MAPK pathway 19-20% 
FAM46C Unknown 6-10% 
BRAF RAS/MAPK pathway 7-12% 
TP53 DNA damage 3-12% 
DIS3 RNA stability 1-9% 
PRDM1 B cell development <5% 
SP140 JAK/STAT signaling 4-6% 
EGR1 Transcription Factor 4-6% 
TRAF3 NF-κB signaling 2-5% 
ATM DNA repair 3-4% 
CCND1 Cell cycle 2-4% 
HISTH1E Histone 1 <3% 
LTB NF-κB signaling 1-4% 
IRF4 B cell development <3% 
FGFR3 RAS/MAPK pathway <3% 
RB1 Cell cycle <3% 
ACTG1 Cytoskeleton <2% 
CYLD Cell cycle 1-2% 
MAX MYC regulation <2% 
ATR DNA repair <1% 
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 Hyperdiploidy is abundantly present in MM where affected patients generally have a 
better prognosis than patients with IgH translocations [49]. Chromosome copy number 
abnormalities seem to generally effect odd numbered chromosomes (3,5,7,9,11,15,19 and 21) 
and can produce chromosome numbers below 48 (hypodiploid) and as high as 74 (near-
tetraploid) [53]. These karyotypic abnormalities appear to remain static throughout disease 
progression in most cases [54]. The specific mechanisms that cause these founding events 
remain less well understood than the mechanisms that produce IgH translocations. Current 
theories regarding the origin of abnormal karyotypes include mitotic errors [53].  
 While the IgH translocations and karyotypic abnormalities outlined above represent 
common primary events in the establishment of pre-malignancy, many secondary translocations 
produced through persisting genomic instability have been well characterized at disease 
diagnosis and relapse. A prime example of this is the proto-oncogene MYC which is translocated 
in 3-4% of MGUS/smoldering MM patients and 15-20% in newly diagnosed MM patients [55]. 
These translocations often occur with Ig-encoding genes IGH, IGL and IGK and other genes with 
strong promotors including FAM46C, FOXO3 and BMP6 [48].  
 Copy-number variations (CNVs) represent an additional class of frequent MM 
chromosomal abnormality that can span from small focal deletions/duplications to events 
effecting entire chromosome arms [56]. There are many documented CNVs and some regions 
appear to be affected more frequently than others [1,49,56]. For example, gain/amplification of 
1q21 has been observed to minimally contain 679 genes including several oncogenes such as 
CKS1B and ANP23E. Deletions of the short arm of chromosome 1 (most often 1p12 or 1p32) 
occur in 30% of MM patients. This region contains several important tumor suppressors including 
FAM46C (protein translation), CDKN2C (cell cycle) and FAF1 (apoptosis). Deletion 17p, which 
removes the classic tumor suppressor TP53, can be present in roughly 10% newly diagnosed 
MM and up to 80% relapsed MM. Deletion 13q occurs in 40-50% of MM patients (more commonly 
in IgH translocated MM) where minimal loss includes the tumor suppressor RB1.  
1.3.2 – Somatic Mutations 
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 Acquisition of multiple oncogenic mutations is a hallmark of all cancers and MM is no 
exception. Several recent massive parallel sequencing studies have cataloged a large number of 
reoccurring mutations in MM [40,42,44,47]. Oncogenic mutations are generally (but not 
exclusively) divided into two categories: gain-of-function mutations that constitutively activate pro-
growth signaling and loss-of-function mutations that suppress or abrogate tumor suppressor 
functions.  
Among the genes identified in sequencing studies are KRAS and NRAS which harbor 
gain-of-function mutations in MM (~20% each). KRAS/NRAS mutations are found in many cancer 
types and are well characterized for constitutively promoting growth through the RAS/MAPK 
signaling cascade. BRAF gain-of-function mutations are less common (6-12% of cases) but also 
act through the RAS/MAPK pathway. Together, KRAS, NRAS and BRAFF somatic mutations 
occur in about 40% of MM cases [48]. Despite being the most commonly mutated genes 
KRAS,NRAS and BRAF in MM, sub-clonal analysis has revealed that these mutations (mean 
cancer clonal fractions at ~30%) are unlikely to represent founding events but rather contribute to 
progression as secondary lesions [44]. 
Several important tumor suppressors, many of which are also frequently reduced via 
recurring CNVs in MM, harbor recurring loss-of-function mutations. These include TP53(3-12%), 
RB1(2-3%), PTEN, CDKN2C and CDKN2A [1,40,44]. 
 Network analysis performed on recurringly mutated genes has also elucidated several 
pathways that are biologically significant for MM. For example, the NF-κB pathway is a significant 
proliferation-promoting signaling pathway for MM and several genes with important functions in 
this pathway are frequently mutated including TRAF3 (2-5%), CYLD(1-5%), MAP3K14, BIRC2, 
BIRC3, IKBKB and others [1,40,44]. 
Several genes encoding epigenetic modifiers are also frequently mutated in MM [57–60]. 
This subject is discussed below.  
 
1.4 – The Epigenetic Landscape of Myeloma: Characteristics and Therapeutic Strategies 
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 The scientific community has long sought to understand the myriad of mechanisms 
malignant cells exploit to escape the homeostatic mechanisms that block overproliferation and 
evade eradication by the host immune system and therapy. Mutations and chromosomal 
abnormalities have been understood to drive cancer progression, yet exhaustive efforts to 
characterize cancer genomes have yet to provide a full picture of cancer biology. In recent 
decades, a growing understanding of epigenetics has fomented a new and important area of 
cancer research.  Epigenetics, the sum total of all regulatory control of gene expression, is 
facilitated by several increasingly understood mechanisms including chemical modifications to 
DNA, post-translation histone modifications, histone composition/deposition and non-coding 
RNAs. A surge of interest in understanding cancer epigenetics has prompted the development of 
many compounds and strategies to study and target epigenetic mechanisms. It is now widely 
accepted that epigenetic abnormalities are abundantly present in cancer and are critically 
important for oncogenesis and disease progression. MM is no exception [57–60] (Table 2). As 
with other cancers, therapeutic strategies that target and exploit the epigenome have gained 
immense momentum in recent years. This has prompted many recent studies that have begun to 
elucidate the highly complex landscape of the myeloma epigenome.  
1.4.1 – DNA Methylation 
 DNA methylation is one of the longest studied epigenetic mechanisms [61]. DNA 
methylation occurs at CpG sites (cytosine and guanine nucleotide pairs, in that order) where a 
methyl group is covalently added at the carbon-5 position of cytosine (5mC). This modification is 
predominantly restricted to intronic and intragenic CpG sites in healthy cells. In pathological 
contexts, large CpG clusters adjacent to transcription start sites, termed CpG islands (CPGIs), 
can be methylated to repress transcription initiation at the transcription start sites of adjacent 
genes. DNA methylation and demethylation is facilitated by DNA methyltransferases (DNMT1, 
DNMT3A and DNMT3B) and the TET protein family (TET1, TET2 and TET3) respectively. 
DNMT1 and DNMT3A are responsible for de novo DNA methylation while DNMT1 maintains DNA 
methylation after DNA replication. DNA-methylation was originally described to be a permanent 
genomic modification, however recent descriptions of demethylation via TET-induced base-
14 
 
excision repair casts doubt on global 5mC permanency. DNA methylation is an important control 
mechanism that has rolls in differentiation, tissue specific gene expression, X-chromosome 
inactivation, silencing of transposable elements and genomic imprinting [61]. 
 Many studies have attempted to characterize DNA methylation differences between 
heathy malignant cell types including healthy/malignant plasma cells. In some cases bisulfite 
sequencing has been used to measure global DNA methylation (the methylome).Generally, 
abnormalities in DNA methylation drive cancer progression through global hypomethylation and 
hypermethylation of tumor suppressor gene promotors [62]. In MM, several studies suggest that 
promotor hypermethylation indeed occurs at known tumor suppressor gene promotors and 
furthermore global hypomethylation/promotor hypermathylation gradually increases through the 
pre-malignant stages of MM, peaking in plasma cell leukemia [63–67]. Effected tumor 
suppressors are enriched in critical pathways/processes including cell cycle, DNA repair, 
apoptosis and important signaling cascades [58]. Promotor hypermethylation of SOCS-1 and 
DAPK have been reported to be early drivers of MM pathogenesis [65]. Interestingly, in a few 
cases hypomethylation of oncogene promotors (e.g. JAG2) has also been implicated as 
pathogenic in MM [68]. 
 DNA methylation is also thought to contribute to MM progression by regulating other 
epigenetic mechanisms. Hypermethylation has been demonstrated to restrict the expression of 
tumor suppressor microRNAs, which can be reversed by inhibitors of DNA methylation (i.e. 5-
azacytadine) [69–71]. It is also clear that DNA methylation and histone modifications share a 
regulatory relationship [62,72]. For example, DNA methylation seems to co-localize with loci 
harboring the repressive histone modification H3K27me3 (tri-methylated histone 3 lysine 27) and 
disruption of DNA methylation dramatically alters global H3K27me3 localization [72,73]. 
Somatic mutations in DNA methylation modifiers have been reported. A recent study 
examining whole exomes of 463 MM patients enrolled in the UK NCRI Myeloma XI study found 
that about 4% of those patients harbored a somatic mutations in DNA methylation modifiers [74]. 
Among those genes are TET1, TET2, TET3, DNMT1, DNMT3A, DNMT3B, IDH1 and IDH2. 
Mutations in DNMTs and TETs directly affect DNA methylation and demethylation respectively.  
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Table 2: Common epigenetic abnormalities in MM 
Type of Abnormality Sub-category Notes or examples 
DNA 
Methylation 
 
[61,63,65,67
] 
Global DNA 
methylation 
 Decreases 
gradually 
through disease 
progression 
Mutations frequent in writers 
(DNMT1/3A/3B), erasers 
(TET1/2/3) and indirect 
regulators (IDH1/2). 
Promotor CpG 
island 
methylation 
Hypermethylation  Increases 
gradually 
through disease 
progression 
Hypomethylation Rare examples 
(e.g. JAG2)  
Non-coding 
RNAs 
 
[58,75–77] 
microRNAs 
microRNA 
processing 
DICER 
mutations 
Represses global microRNA 
levels 
Downregulated 
microRNAs 
Targeting 
oncogenes:  
miR-21/181a/106b-cluster 
(PTEN, BIM,p21 and PCAF) 
miR221/222 cluster 
(p27kip1, PTEN, PUMA and 
pKip2) 
Upregulated 
microRNAs 
Targeting tumor 
suppressors:  
Example tumors 
suppressors: CCND1, 
CCND2, NF-κB and AKT3  
Long non-
coding RNAs 
 Very few MM-
specific studies 
MALAT1 overexpression 
Chromatin 
 
[58,60] 
Chromatin 
remodeling 
SWI/SNF complex Mutations in 
CHD2 and 
CHD4 
SWI/SNF and NuRD 
complex members are 
affected by CNVs in ~40% 
of MM cases NuRD complex Mutations in 
ARID1A/4A/5B 
Histones 
 Recurrent 
HIST1H1B-E 
mutations 
Low frequency of core 
histone mutations in MM 
Histone tail 
post-
translational 
modifications 
Histone acetyl 
transferases 
Recurring 
mutations in 
EP300 and 
CREBBP 
CREBBP mutations are 
particularly enriched in 
relapsed MM 
Histone 
deacetylases 
Overexpression 
of HDAC1/2/3/6 
HDAC6 counteracts 
proteasome inhibitors by 
facilitating lysosomal 
clearance of aggresomes  
Histone methyl 
transferases 
MMSET 
(H3K36me2) 
Overexpressed in t(4;14) 
MM or mutated (gain-of-
function) 
EZH2 
(H3K27me3) 
Overexpressed in most 
cases of MM 
G9a (H3K9me3) Overexpressed in MM 
GLP 
(H3K9me3) 
Overexpressed in MM 
NSD1 
(H3K36me2) 
mutated (gain-of-function) 
Histone de-
methylases 
UTX/KDM6A 
(H3K27me3) 
Mutated (loss-of-function) 
KDM3A/B 
(H3K9me3) 
Upregulation drives IRF-4 
and KLF-2 expression 
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IDH1/2 (Isocitrate dehydrogenases 1 and 2) loss of functions lead to aberrant buildup of 2-
hydroxyglutarate, which is known to inhibit DNA demethylases (alpha-ketoglutarate dependent 
dioxygenases) [78]. 
Somatic mutations in these genes may explain abnormal methylomes observed in some 
cases of MM but fails to explain the broader prevalence of aberrant DNA methylation in MM. The 
regulatory contexts and mechanisms that govern changes in DNA methylation during the initiation 
and progression of MM are largely unknown and the broader mechanisms that control global 
methylation patters have yet to be fully elucidated. Given known protein-protein interactions 
between epigenetic-regulating protein complexes and other accumulating evidence, is likely that 
regulators of DNA methylation act in concert with regulators of chromatin dynamics in a complex 
high-dimensional network that has only begun to be fully described [79].  
It is clear that DNA methylation is an attractive therapeutic target for MM. Indeed, DNA 
methyltransferase inhibitors (DNMTi’s) such as 5-azacytidine (AZA, Vidaza) and 2-deoxy-5-aza-
cytidine (DAC, Decitabine, Dacogen) have been evaluated via in vitro and in vivo pre-clinical 
models of MM [80,81]. Furthermore, AZA has been evaluated for efficacy in cancers including 
MM in recent clinical trials (NCT00006019) and encouraging results have prompted the 
development of new more stable DNMTi’s [82].  
1.4.2 – Non-coding RNAs 
 Since the completion of the human genome project scientists have been fascinated by 
the expanse of the non-protein-coding segment of the genome (98% by sequence, when 
including 5’/3’ untranslated transcript regions) [83]. Further study of these regions have revealed 
that this so-called ‘junk DNA’ has important functional significance and that many loci are actively 
transcribed to confer an entire regulatory network of functionally active non-translated (non-
coding) RNAs [84,85]. Non-coding RNAs (ncRNAs) that have structural functions (e.g. tRNAs, 
rRNAs, snRNAs and uRNAs) have been well studied. Regulatory ncRNAs are relatively new 
discoveries. Here regulatory ncRNAs are split into two types: long non-coding RNAs (lncRNAs) 
and microRNAs. 
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 MicroRNAs are small (~22nucleotide) ncRNAs that regulate the transcriptome post-
transcriptionally. MicroRNAs hybridize to specific complimentary sequences in target mRNAs and 
either initiate their degradation or inhibit their translation [86]. MicroRNAs regulate a great number 
of biological functions [87] including many that have a high impact on cancer initiation and 
progression [88,89].  
Several studies have characterized microRNA abnormalities in MM and found that they 
are unsurprisingly altered by the same epigenetic abnormalities and genomic lesions that affect 
coding genes (e.g. mutations, translocations and CNVs) [75,76,90–92]. Additionally it appears 
that genes that encode core components of the microRNA machinery (e.g. DICER) may also by 
aberrantly repressed through the progression of MM [93]. 
MicroRNAs contribute to MM progression in several ways [75,76,90–92]. Many miRNAs 
upregulated in MM target tumor suppressors to promote malignancy. For example miR-21, miR-
181a and the miR-106b cluster are known to target PTEN, BIM, p21 and PCAF. The miR-221/222 
cluster promotes MM growth by targeting p27kip1, PTEN, PUMA and p57kip2 [94]. Other 
microRNAs with tumor suppressor functions are underexpressed in MM. For example CCND2 
mRNA (cyclin D2) is targeted by several miRNAs that are underexpressed in MM including miR-
196b, miR-135b, miR-320, miR-20a, miR-19b, miR-19a and miR-15a [95]. Other downregulated 
miRNAs share oncogenic targets such as NF-κB, AKT3 and cyclin D1 [58].  
 LncRNAs, the most numerous and least understood class of ncRNAs, are regulatory 
transcripts that coordinate with transcription factors and co-transcriptional regulators to control 
gene expression [96]. Unlike microRNAs, the direct consequence of lncRNA regulation can be 
either enhancing or repressing depending on the context. Recent studies have begun to reveal 
numerous roles for lncRNA dysfunction in cancer [97–100]. 
 Only a small number of studies have explicitly examined lncRNA dysregulation in MM, 
yet despite this, it is clear that this class of ncRNA is abnormally regulated in MM to a significant 
degree [101,102]. One recent study found that in a small number of newly diagnosed MM patient 
samples over 3000 lncRNAs were differentially expressed compared to non-malignant controls 
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[103]. As a specific example, lncRNA MALAT1 is overexpressed in MM and coordinates with the 
Sp1 transcription factor to positively regulate the TGF-β signaling pathway [104]. 
1.4.3 – Chromatin Organization and Histone Modifications 
 Transcriptional regulation in eukaryotes relies, in part, on regulating the accessibility and 
compaction of chromatin. The fundamental unit of chromatin, the nucleosome, comprises of a 
core histone (H2A, H2B, H3 and H4) octamer linked by histone H1 and wrapped twice by a total 
of 147bps of genomic DNA [105]. The human genome encodes for over 70 different histone 
proteins and composition/remodeling of nucleosomes is an increasingly appreciated facet of 
epigenetic control [106,107].  
Core histones have accessible N-terminal tails that are substrates for post-translational 
modifications (PTMs) (methylation, acetylation, phosphorylation, sumoylation, citullination, 
biotinylation, ribosylation and ubiquitination) at arginine, lysine and serine residues [108]. Histone 
tail PTMs regulate several essential functions including higher-order chromatin 
organization/compaction, DNA damage repair, sequestration of epigenetic/co-regulatory 
complexes and regulation of transcription [109]. Specific and global changes in histone tail PTMs 
are important for controlling expression of critical genes during development, maintaining tissue-
specific gene expression and regulating higher-order nuclear organization [109]. Histone PTMs 
also present a means for facilitating broader context-specific gene expression changes that 
govern higher order processes (e.g. halting proliferative ‘stemness’ after terminal differentiation).  
The numerous permutations of nucleosome compositions and histone PTMs allows much 
more regulatory information to be stored laterally along genomic DNA than is possible to convey 
with chemical modifications (i.e. methylation) to genomic DNA [107,110]. This sum total of this 
regulatory information along the genome is referred to as the histone code. As seen between 
DNA methylation and histone modification, a large and poorly understood global network of 
crosstalk exists between different pathways that modify and coordinate with histone modifications 
[23,111]. Understanding how these pathways focally and globally coordinate while sensing 
endogenous/exogenous signals and regulating the composition/plasticity of the histone code 
remains an immensely challenging systems biology problem.  
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Chromatin had classically been thought to exist in one of two states: active euchromatin 
and inactive heterochromatin. This notion, however, is an oversimplified description of the high-
dimensional complexity inherent in the histone code. Recent studies have updated our 
understanding of chromatin classes to include several more nuanced distinctions based on 
clustering of histone PTMs and occupancy of chromatin binding proteins [112,113]. This includes 
chromatin found at ‘bivalent promotors’ that is poised for activation [114,115].  
Extracting functional significance from the histone code begins by understanding the 
characteristics inherent in histone PTMs where some generalities can be drawn [110].  For 
example, acetylation of histone tail lysine (K) residues and phosphorylation on histone tails is 
generally considered a mark of transcriptionally active chromatin (e.g. H3K27ac). Additionally, 
histone tails can be methylated at lysine or arginine residues, however, the consequence of this 
modification (e.g. activation via H3K4me3 or repression via H3K27me3) depends on the specific 
residue and broader chromatin context [116]. Modifications at specific residues are numerous and 
only partially functionally characterized. The latest release (2010) of the human histone 
modification database includes 43 location specific histone modifications in humans [117]. While 
context may dictate that not all permutations of these modifications appear in normal histone 
codes, the amount of information that can be conveyed with these modifications is immense.  
Understanding how histone modification abnormalities arise in different cancers begins 
by identifying the source: histone modifying complexes [118]. Numerous histone modifications 
require equally numerous histone modifying proteins. According to HIstome, a histone infobase 
[108], there are currently 13 classes encompassing the roughly 150 known histone modifying 
enzymes. Proteins that regulate and modify histone PTMs generally fall into one of three broad 
classes: epigenetic readers, writers and erasers [119,120]. Epigenetic readers are proteins that 
bear structural domains that recognize and bind specific histone tail PTMs. Examples of histone 
readers include bromodomain (recognizes acetylated lysines) and chromodomain (recognize 
methylated lysines) proteins. Epigenetic writers and erasers are, as the monikers imply, enzymes 
that catalyze the addition and removal of histone PTMs. For example, regarding histone 
acetylation, histone acetyltransferases (HATs) are the writers and histone deacetylases (HDACs) 
20 
 
are the erasers.  Many histone modifying enzymes also have or complex with proteins harboring 
reading domains, which establishes complex interactions between specific modifications and can 
also facilitate context-specific lateral elongation of certain histone modifications along the genome 
[111,119]. 
In MM many regulators/facilitators of histone modification are known to be abnormally 
regulated by or directly affected by genomic lesions [57–60,74,121].  
Perhaps the most intuitively consequential drivers of histone dysfunction are somatic 
mutations in the genes that encode the histone proteins. Recent large scale sequencing efforts in 
MM have identified recurring mutations in HIST1H1B-E, a gene encoding the linker histone H1, at 
a frequency of up to 6% of cases examined [74]. Mutations in core histones were also detected, 
albeit at a much lower frequency. These histone H1 mutations were often missense mutations 
located in the DNA binding domain, which is suggested to be driver mutation in other B-cell 
malignancies [122,123]. How the disruption of nucleosome structural organization and chromatin 
dynamics drives malignancy remains largely unclear. 
Processes that track genomic DNA, such as transcriptional activation, require structural 
adjustments of nucleosome occupancy. These events require large ATP-dependent dependent 
protein complexes known as chromatin remodeling complexes that represent another functional 
aspect of histone regulation. Two of these complexes, NuRD transcriptional repressive complex 
and SWI/SNF remodeling complex, have been found to have members that are frequently 
misregulated in MM [74]. NuRD members CHD2/CHD4(~2% each) and SWI/SNF members  
ARID1A(1.3%), ARID2(1.3%), ARID4A and ARID5B were shown to be recurrently mutated. 
SWI/SNF mutations in particular widespread among other forms of cancer with a frequency 
rivaling TP53 mutations [124]. Notably, mutations in SMARCA4 (a SWI/SNF complex member) 
are observed in a much higher proportion in cases of MM relapse, suggesting a potential role for 
driving aggressive disease and drug-resistance [74]. Considered together, NuRD and SWI/SNF 
complex members are affected by CNVs at a very high rate (~40%) in MM [74]. Chromatin 
remodeling is inherently much more difficult to study at a systems level than covalent 
modifications to DNA and histones. For this reason the full scope of how chromatin remodeling 
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contributes to epigenetic homeostasis remains elusive. Some mechanisms, such as an essential 
role in facilitating DNA damage repair, are thought to contribute to the oncogenic effects of 
abnormal chromatin remodeling [124]. Chromatin remodeling is a very attractive target for cancer 
therapy, however there are currently no therapeutic strategies that can specifically target these 
complexes. 
Histone acetyltransferases (HATs) and deacetylases (HDACs) covalently deposit and 
remove acetyl groups to histone tail lysine residues [125]. Histone tail acetylation is generally 
considered to be a chromatin-activating modification. Transfer of acetyl groups from acetyl-CoA 
to lysine residues on histone tails by HATs neutralizes the highly positive charge of histones and 
thereby lowering the interaction with negatively charged genomic DNA and de-condensing 
chromatin. HDACs are a diverse family of enzymes that canonically catalyze the removal of 
acetyl groups from histone tails [126,127]. There are a total of 18 HDACs divided into four classes 
based on structural similarity to yeast homologs and sub-cellular localization. Class I, II and IV 
HDACs are considered the ‘classical HDACs’ that are zinc-dependent. Class III HDACs on the 
other hand are known as sirtuins; a family of NAD+-dependent enzymes that are insensitive to 
HDAC inhibitors (HDACi’s). HDACs lack inherent DNA binding and therefore require coordination 
with other proteins (e.g. transcription factors) to access and modify DNA. Class I HDACs, 
consisting of HDAC1, HDAC2, HDAC3 and HDAC8, are ubiquitously expressed, exclusively 
nuclear HDACs that are responsible for canonical removal of acetyl groups from histone tails. 
Class II HDACs have limited tissue specific expression and are subdivided into class IIa (HDAC4, 
HDAC5, HDAC7 and HDAC9) and clad IIb (HDAC6 and HDAC10). Class IIa HDACs can, under 
the control of regulatory kinases, shuttle between the nucleus and the cytoplasm; a process that 
governs the non-canonical acetylation of non-histone substrates [127]. Interestingly, this class of 
HDACs have low catalytic activity that appears to be dispensable for repression of gene 
expression [127]. Class IIb HDACs are exclusively cytoplasmic, where HDAC6 is the main 
cytoplasmic deaminase in mammalian cells and very little is known about HDAC10. HDAC6 
(unique among HDACs for its two catalytic domains and C-terminal zinc finger) has several 
known deacetylation targets including cytoskeletal proteins, transmembrane proteins and 
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chaperones. Class IV of HDACs consists only of HDAC11, about which very little is known 
beyond its limited tissue-specific expression and cytoplasmic sub-cellular localization [127]. 
Both HATs and HDACs have described dysregulation in MM. Mutations in genes 
encoding the HATs EP300 and CREBBP have been described in MM [74] and other B-cell 
malignancies [128]. Abnormalities in CREBBP are particularly enriched in relapsed MM, 
suggesting possible impact on drug resistance [74]. Several HDACs including HDAC1, HDAC2, 
HDAC3 and HDAC6 have been reported to be overexpressed in MM and confer a poor prognosis 
[129]. The specific targets of MM expressing HDACs/HATs and how they promote disease 
progression are not certain since these regulators target thousands of genes and thousands of 
non-histone targets [130]. Many of the known nuclear HDAC/HAT targets are associated with MM 
pathogenesis including p53, HSP90, NF-κB, RUNX3, STAT-3, E2F1 and MYC [131]. HDAC6 has 
gained particular interest as a target in MM due to its role in facilitating aggresomal clearance 
through the lysosome. Inhibiting this process is thought to block a path for MM cells to escape 
aggresomal buildup generated from proteasome inhibition, a standard-of-care therapy for MM 
discussed more extensively below. Synergy between HDAC inhibition and proteasome inhibitors 
has been observed in pre-clinical models of MM [132,133]. 
Accumulating evidence supporting HDACs as attractive drug-able targets for MM, 
especially in combination with proteasome inhibition, prompted several clinical evaluations of 
HDACi’s in MM [121]. Panobinostat (Farydak), a pan HDAC inhibitor, demonstrated significant 
(albeit modest) enhancement of response and prompted the recent FDA approval of panobinostat 
for patients who have received at least two previous regimens [134–136]. 
 Histone methylation is more complicated that histone acetylation as the functional 
consequence of methylation can be either repressive or enhancing [120]. Histone lysine 
methylation was first reported to be involved in transcriptional regulation in the 1960s [137], 
however it was not until after the turn of the century that the first histone methyltransferase 
(HMT), SUV39H1, was identified [138]. The catalytic SET domain identified in this first HMT lead 
to homology searches that illuminated many more HMTs. Turnover of histone lysine methylation 
was presumed to be extremely slow until the first histone demethylase, LSD1, was discovered 
23 
 
and JmjC domains were described as a key identifying domain for that class of enzymes 
[139,140]. Histone methylation is unlike histone acetylation in that the controlled addition of one, 
two or three methyl groups to a lysine residue (mono-, di- and tri-methylated) does not change 
the electric charge of the amino acid side chain. Therefore histone lysine methylation does not 
directly affect nucleosome organization but rather serves as a signal for epigenetic readers [120]. 
Indeed, there are a significant number of domains that recognize these modifications including 
PHD, chromo, tudor, PWWP, WD40, BAH, ADD, ankyrin repeat, MBT and zn-CW domains [141].  
 The most well studied histone modifier in MM is so named: multiple myeloma SET 
domain (MMSET; also known as NSD2/WHSC1). MMSET is a HMT that is overexpressed in MM 
due to being placed proximal to the IgH strong promotor in t(4;14) translocations that occurs at a 
frequency of 15-20% [142]. MMSET overexpression directly leads to accumulated methylation of 
its target (H3K36me2). In other instances, particularly in relapsed MM, MMSET and NSD1 (a 
related HMT) harbor gain of function mutations that show elevation of H3K36me2 [121,143]. 
MMSET has also been repeatedly shown to be essential for DNA damage repair pathways. 
Additionally, cells that overexpress MMSET are exceptionally tolerant of DNA damage; a 
mechanism that may contribute directly to MM pathogenesis and resistance to chemotherapy 
[144]. MMSET regulation of transcription seems to modulate several oncogenic pathways that 
promote malignant progression in many forms of cancer [145]. Overexpression of MMSET has 
been shown to also have impacts on the global distribution of other histone modifications 
[146,147], suggesting that MMSET overexpression may lead to pleiotropic dysregulation of other 
epigenetic pathways. Lastly, MMSET has been shown to complex with the KAP1 corepressor and 
HDAC1/2 to repress the MYC-targeting microRNA miR-126 [148]. MMSET has long been 
considered a priority target in MM, especially in cases of t(4;14), however no compounds have 
been developed that specifically target MMSET.  
 Methylation of H3K9 is essential for the formation of heterochromatin where it occupies 
promotors of repressed genes and gene bodies of active genes. H3K9me3 is unique among 
repressive tri-methyl PTMs in that it occupies both silenced and active genes [149]. HMTs 
responsible for H3K9 methylation include SUV39H1, SUV39H2, G9a and GLP. Associated 
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demethylases include KDM3A, KDM3B and LSD1 [120]. Aberrant activity of both H3K9 HMTs 
and demethylases have been described for MM. Specifically G9a and GLP appear to be 
overexpressed in MM and KDM3A demethylation upregulates the oncogenic transcription factors 
IRF-4 and KLF-2 to sustain cell adhesion [150,151]. 
 Tri-methylation of H3K27 is a well characterized repressive mark. Di- and tri-methylation 
of H3K27 is catalyzed by the HMTs EZH1 and EZH2, with EZH2 having a clear role in MM 
progression [58]. The relationship between aberrant EZH2 activity and MM progression is 
discussed extensively in a separate section below.  
Further implicating an oncogenic role for H3K27me3, the H3K27 demethylase 
KDM6A/UTX harbors a recurring loss-of-function mutation in MM [152,153].  KDM6A/UTX 
complexes with a number of other histone modifying/remodeling complexes including H3K4 
(activating) HMTs (KMT2, COMPASS family proteins, HATs (P300) and chromatin remodelers 
(SWI/SNF) to tightly couple the regulatory switch between chromatin activation (H3K4) and 
repression (H3K27) [58].  
1.4.4 – EZH2 as a Potential Therapeutic Target in Myeloma 
 Enhancer of zeste homolog 2 (EZH2) is the HMT that catalyzes di- and tri-methylates 
histone 3 at lysine 27 (H3K27); a mark associated with repressed chromatin. EZH2 is the core 
catalytic subunit of the polycomb repressive complex 2 (PRC2) [154]. Polycomb complexes 
(PRC1 and PRC2) are named for the Drosophila mutant phenotype displaying improper body 
segmentation [155,156]. Unlike PRC2, which methylates H3K27, PRC1 monoubiquitylates 
H2AK119 via its core ubiquitin ligases RING1A and RING1B [154]. It was long thought that the 
two polycomb complexes interacted through hierarchical recruitment to chromatin, however this 
model has since been debunked [157].  
 PRC2 consists of a core catalytic subunit EZH21/EZH2 and additional complex members 
EED, SUZ12 and RbAp46/48 (also known as RBBP7/4). Unlike most SET-domain 
(methyltransferase) proteins that remain autonomously active, EZH2 adopts an auto-inhibited 
conformation when it is independent from its PRC2 partners (an obligate multimeric complex) 
[158]. EED contains WD-40 repeats that confer high-affinity binding to PCR2’s own catalytic 
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product: H3K27me2/3. This feedback mechanism is thought to confer PRC2’s ability to laterally 
propagate its chromatin modification along adjacent nucleosomes [158].  
PRC2’s global and focal localization to chromatin is known to be developmentally 
regulated, however the specific mechanisms that govern context-dependent localization remains 
elusive [158]. PRC2’s affinity for other epigenetic complexes, methylated CpG islands and RNA 
(seemingly non-specific) have been described and may yet be revealed to play a role in the 
regulation of PRC2 [158].  
EZH2 has also been recently characterized to have several non-canonical functions, 
broadening the scope of it’s regulatory sphere of influence [159]. These non-canonical functions 
have a range of consequences, however they all ultimately act by regulating transcription. For 
example, EZH2 methylates transcription factors (i.e. RORα) at a methyl-degron domain. 
Methylation of the methyl degron sequesters the chromo-domain (monomethyl-lysine binding) 
harboring DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex for ubiquitination and proteolytic 
degradation [160]. Another example of non-histone methylation targets includes the recent 
observation that EZH2 di-methylation of STAT3 at K49 activates IL-6 responsive transcription, an 
oncogenic pathway known to be exploited by MM [161]. Besides canonical and non-canonical 
methylation targets, EZH2 has also been recognized to have non-catalytic functions as a co-
transcriptional regulator. Non-catalytic activity of EZH2 were first suggested through models 
demonstrating a growth advantage in cell lines overexpressing catalytic-null EZH2 [162]. Studies 
identifying more specific mechanisms have also recently highlighted non-catalytic rolls for EZH2 
as a co-transcriptional regulator [163,164].  For example, in a breast cancer model EZH2 was 
also shown to act as a catalytic-independent co-activator of MYC and CCND1/2transcription by 
coordinating beta-catenin (Wnt pathway) and estrogen receptor alpha at gene promotors [163]. 
Finally, a novel non-catalytic function for EZH2 was recently described in mice where EZH2 binds 
and triggers the cleavage of RNA transcribed from B2 SINE retrotransposons in response to heat 
shock, freeing transcription of stress-response genes [165]. The mechanisms that direct or 
restrict EZH2 to certain targets remains generally unclear, however, one recent study has 
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proposed a specific phosphorylation modification on EZH2 may directs its activity towards non-
catalytic co-transcriptional activation [166]. 
Canonically EZH2 is responsible for silencing gene transcription and has been 
associated with regulating thousands of genes [158]. EZH2 is considered a positive regulator of 
proliferation and ‘stemness.’ For example, it is critical for maintaining proliferative capacity during 
clonal expansion/affinity maturation of germinal center B cells and after which it is gradually 
silenced preceding terminal differentiation [167]. While the full scope of EZH2’s regulatory impact 
is still unclear, it has become abundantly clear that EZH2 is aberrantly active in many forms of 
cancer. The first evidence for EZH2’s significance in MM came from the observation that EZH2 is 
overexpressed in aggressive MM despite not being appreciably expressed in plasma cells from 
heathy donors [168,169]. Following this observation a previous member of our laboratory 
demonstrated that EZH2 expression is required for the proliferation of growth-factor-independent 
(IL-6 independent) human myeloma cell lines (HMCLs) harboring a RAS mutation [170]. By 
demonstrating that knock-down of EZH2 was sufficient to arrest MM cell line growth our 
laboratory was the first to demonstrate that EZH2 acts as an oncogene in MM. At the time of this 
observation no chemical inhibitors existed that specifically targeted EZH2 and therefore pre-
clinical evaluation of EZH2 ceased.  
Since our initial observation that EZH2 promotes MM growth and proliferation, 
corroborating evidence has continued to accumulate supporting EZH2 as a target in many 
cancers including MM [159,171–173]. Generally, EZH2 is thought to promote malignant 
proliferation by silencing expression of tumor suppressor genes [172]. Interest in the oncogenic 
properties of EZH2 have been of particular interest in lymphomas where an EZH2 suffers a 
recurring gain of function mutation at frequencies as high as 21% in diffuse large B cell 
lymphomas [174–176]. In cases of EZH2 gain-of-function mutation an enlargement of the 
catalytic pocket biases the catalytic activity of mutant EZH2 towards tri-methylation over di-
methylation. This mutant allele always appears as a heterozygote as it requires unmodified EZH2 
to populate histones with the di-mehtyl mark [177].  
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In MM several studies have presented additional lines of evidence that EZH2 is 
aberrantly active in MM [77,152,178–185]. One of the initial studies performed ChIP-seq assays 
(targeting H3K27me3) on MM patient samples and cell lines. This study observed that genes 
marked by H3K27me3 were highly enriched within the profile of underexpressed genes in MM. 
Furthermore, applying a non-specific methyltransferase inhibitor 3-Deazaneplanocin (DZNep), 
reactivated many of the repressed genes [186]. DZNep was an early tool for studying HMT 
function but lacked selectivity to draw specific conclusions.  
Accumulating evidence suggested that certain cancers (especially those harboring gain-
of-function mutations) exploit EZH2 for growth and therefore may be addicted to EZH2 regulation. 
This ultimately fomented the design of several small compounds that specifically inhibit EZH2 
over other HMTs. These small compounds include EPZ-6430 (Tazemetostat, Epizyme), GSK-126 
(GSK) and UNC1999 [184,187–189]. UNC1999 has much less selectivity for EZH2 over EZH1 
than GSK-126 and EPZ-6438 and is therefore considered a dual inhibitor. It is important to note 
that no currently published studies have yet demonstrated any significant role for EZH1 in 
myeloma. In all cases, these compounds inhibit EZH2 catalytic activity by blocking accessibility of 
the catalytic SET domain. New analogs and unique compounds that target EZH2 or EZH2 and 
EZH1 together have continued to be developed and tested [159,178,190] 
Development of these inhibitors has prompted many studies to evaluate the pre-clinical 
efficacy of EZH2 inhibitors (EZH2i’s) in many cancers including EZH2. These inhibitors provided 
new specificity in targeting EZH2 and also lacked artifacts seen in the application of DNZep such 
as the degradation of EZH2 protein itself (not observed with new inhibitors). These inhibitors all 
demonstrated efficacy in cell lines at doses in the nano-molar to micro-molar range and induced 
maximal global demethylation of H3K27 after 2-3 days. 
Several studies have used these new inhibitors to better understand the transcriptomic 
footprint of EZH2 in MM. Efforts have been reported to profile both deactivating H3K27me3 and 
activating H3K4me3 between healthy and malignant plasma cells to identify repressed and 
bivalent genes unique to MM [182].  These data, when compared to gene expression changes 
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induced by EZH2 inhibition, demonstrated that EZH2i can reverse repression of genes marked by 
H3K27me3. This was especially true for genes harboring bivalent histone modifications [182].  
Other recent efforts that have tested EZH2i’s to MM cell lines have described single 
agent efficacy in a significant sub-population of myeloma cell lines and in vivo models. Several 
drug-induced effects described by these studies have included apoptosis, de-differentiation, 
upregulation of tumor suppressors, downregulation of oncogenic pathways, modulation of cell 
adhesion molecules, cell cycle arrest, targeting of cancer stem cells and selective sensitivity of 
KMD6A/UTX mutant myelomas [152,178–180,182–185]. 
Pre-clinical success with EZH2 inhibitors in lymphoid malignancies, namely lymphomas, 
has prompted the advancement of two EZH2 inhibitors (EPZ-6438: NCT02860286 and GSK-126: 
NCT02082977) into early-phase clinical trials.  
While application of these compounds seems promising, there are still many open areas 
of inquiry that need to be addressed regarding the specific mechanisms that drive EZH2 to 
become overexpressed and aberrantly active in MM. Additionally, it remains unclear how 
predictable EZH2i transcriptomic between different cancers and between different patients of the 
same cancer.  
 
1.5 - Current Therapeutic Strategies for Management of Newly Diagnosed Myeloma  
Treatment strategies for MM have evolved since the 1960s as our understanding of 
myeloma biology has grown [191]. The last decade in particular has seen a large increase in the 
number of drugs and therapeutic approaches that are being evaluated in part due to increased 
understanding of drug resistance mechanisms, high-throughput efforts to test vast quantities of 
new compounds, personalized medicine approaches to diagnosis/treatment and the advent of 
new technologies (i.e. gene editing techniques and promising immunotherapies). Additionally 
attitudes towards treatment have also moved towards a more conscious consideration for quality 
of life for patients and developing more accurate risk assessments for treatment. MM is still 
largely considered incurable despite recent advancements that have increased the median 
survival [3]. 
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Early treatment regimens for MM included alkylating agents and corticosteroids; 
compounds which are still applied to therapy today [192]. Today, standard-of-care therapy has 
several options that are largely determined by the level of risk inherent in a particular myelomas 
genomic classification and other factors including age and health [193].  One option is for patients 
to undergo autologous stem cell transplant (ASCT) [194,195]. ASCT involves initial cycles of 
chemotherapy, stem cell collection, ASCT and finally 2+ years of chemotherapeutic maintenance. 
Traditionally ASCT eligibility have dictated the initial therapies used as more aggressive therapies 
would decimate the stem cell population needed for harvesting prior to transplant. Today, 
however, therapies are being changed and optimized to reduce undue hematological toxicity and 
therefore we are approaching a convergence of treatment options between ASCT-eligible and –
ineligible patients.  
 The list of drugs currently used to treat MM has expanded significantly in recent decades 
to include proteasome inhibitors (Bortezomib, Carfilzomib and Ixazomib), immunomodulatory 
drugs (Thalidomide, Lenalidomide and Pomalidomide), monoclonal antibodies (Daratumumab 
(anti-CD38) and Elotuzumab (anti-SLAMF7)), HDAC inhibitors (Panobinostat), alkylating agents 
(Melphalan, Cyclophosphamide, Bendamustine) and corticosteroids (Dexamethasone and 
Prednisone) [191].  
 Currently, the combination of proteasome inhibitors with immunomodulatory drugs is 
considered to be the most efficacious treatment strategies to treat newly diagnosed MM. 
Specifically, bortezomib combined with lenalidomide and dexamethasone (VRD) has become the 
preferred treatment for patients who can tolerate a three drug cocktail. It is expected that second 
generation proteasome inhibitors (carfilzomib/ixazomib) will soon replace botezomib due to oral 
availability. For ASCT ineligible patients, bortezomib and immunomodulatory drugs are often 
combined with alkylating agents and corticosteroids [191].  
 Immunotherapy has the potential to revolutionize cancer treatment. Several exciting new 
anti-MM therapies are currently under development that harness the host immune system to 
eliminate malignant plasma cells. One example is the momentum behind evaluating PDL 
inhibitors in MM [196]. The PD-1/PD-L1 pathway is a negative regulator of the immune system 
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that is exploited by MM to evade the host immune system. Pembrolizumab (an anti-PD1 
antibody) has been applied in several ongoing clinical trials. While the therapeutic antibody does 
not demonstrate strong single agent efficacy in MM, it may work cooperatively with another 
immune-therapy currently under development for MM: CAR T cells [196].  Chimeric antigen 
receptor (CAR) T-cell therapy is a very promising strategy for treating MM. Many distinguishing 
markers/regulators have been identified as specific targets in MM (e.g. MYC or MMSET), yet 
many lack small compounds that target them. CAR T cell therapy changes this by harvesting T-
cells from a patient and engineer them to recognize specific cell surface markers, targeting those 
cells for intervention by the host immune system. Specifically in MM, CAR T cells are engineered 
to recognize the B-cell maturation antigen (BCMA) [197]. Adoptive T cell-based therapies have 
generated a lot of excitement in the field of MM therapy and updates (February, 2018) from an 
ongoing phase one clinical trial suggest that among patients treated at the highest doses, 94% 
show complete or partial remissions [198]. 
 
1.6 – Proteasome Inhibitors and Drug Resistance  
 Drug resistant relapse in MM in nearly inevitable. In some cases patients are entirely 
refractory to initial standard of care therapies. Nearly 25% of MM patients attain only short 
treatment responses and have a median overall survival of only 3 years [191]. The persistent 
problem of resistant and refractory MM highlights the need to understand the mechanisms that 
underpin resistance to the most widely used anti-MM therapies.  
1.6.1 – The Ubiquitin Proteasome System and Anti-Myeloma Proteasome Inhibitors 
 Proteasome inhibitors are among the most widely used therapies to treat newly 
diagnosed MM. The proteasome is a large barrel shaped holoenzyme that catalyzes the 
proteolytic degradation of cellular proteins as a component of the ubiquitin proteasome system 
(UPS) [199,200]. The mammalian UPS comprises of several hundred ubiquitin ligase enzymes 
(one E1, 50+E2 and 500+ E3 ubiquitin ligases). The diversity of regulatory elements within the 
ubiquitination ligase system presents a complex regulatory network controlling when and why 
cellular proteins are targeted for proteolytic turnover. Once ubiquitinated, targeted proteins are 
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shuttled to the 26S proteasome complex. The 26S proteasome comprises of a 20S core barrel 
and one or two 19S regulatory subunits. Proteins arriving at the proteasome are bound, de-
ubiquitinated and unfolded by a 19S regulatory subunit, after which the protein is processed 
linearly through the proteolytic core of the proteasome where it is digested by the catalytic ring of 
beta-subunits. Generally, this process is thought to provide cells with a robust mechanism for 
maintaining protein homeostasis. The proteasome is a highly conserved complex that senses and 
controls a myriad of cellular processes [199]. 
 Bortezomib (Bz, Velcade), the most commonly applied proteasome inhibitor used to treat 
MM. Bz (and second generation proteasome inhibitors) targets the PSMB5 beta subunit of the 
20S proteasome core and inhibits it chymotrypsin-like catalytic activity [199].   
Malignant plasma cells are thought to be uniquely sensitive to proteasome inhibition for a 
number of reasons. First, plasma cells function to produce and secrete high quantities of Ig 
proteins. To accomplish this plasma cells adopt morphological changes that yield a large 
accentuated endoplasmic reticulum (ER). Such a high degree of protein production in turn yields 
undue ER-stress from occasionally misfolded proteins. While plasma cells can manage this high 
degree of turnover, they are uniquely sensitive to any perturbation in their ability to clear 
misfolded proteins [201]. Additionally MM cells, like other types of cancer, exploit certain signaling 
cascades to drive and sustain proliferation. Several such pathways require the UPS for turnover 
to convey a signal. A classic example of this is in the NF-κB pathway where ubiquitination and 
proteolytic degradation if the IκB are required for nuclear localization of the transcription factors 
p65/p50 [202]. Other processes and pathways that require proteasome function for complete 
signaling include cell cycle (p21, cyclins and p27Kip1), oncogenesis (p53 and bax), apoptosis 
(Bcl-2, XIAP, cIAP), gene expression (c-Jun, E2F1, beta-catenin) and many others [201]. 
1.6.2 – Proteasome Inhibitor Resistance  
 Resistance to proteasome inhibitors can be achieved by a great number of mechanisms. 
Treating a patient with proteasome inhibitors provides the sub-clonally diverse population of 
malignant plasma cells residing in the bone marrow to undergo a phase of selection. There 
remains some debate as to whether resistance in some instances is ‘acquired’ de novo upon drug 
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treatment or if selection propagates a minority population harboring ‘innate’ resistance to the 
inhibitor, however recent characterization of myelomas diverse sub-clonal architecture 
increasingly implicates the latter [48]. Furthermore, some recent evidence suggest that drug 
resistant relapse may arise from an extreme minority population of cancer stem cells that 
maintain abnormal quiescence while slowly repopulating the bulk tumor with rapidly dividing drug-
resistant cells [203]. 
 Regardless of how resistant MM cells arise within the bulk tumor during treatment there 
are many ways that individual cells can overcome or refract perturbation of the UPS [204].  This 
most theoretically intuitive mechanism for Bz resistance is a somatic mutation in the targeted 
PSMB5 subunit, however such mutations are rarely seen in MM cases suggesting that there are 
much more easily adopted means to resistance [205]. Indeed, resistance to proteasome inhibitors 
often does not confer a total blockade of drug action but rather elevates the general tolerance for 
ER-stress. While somatic mutations in proteasome subunits fail to explain recurring resistance 
there is evidence to suggest that proteasome subunits are altogether upregulated to compensate 
for the increased ER-stress. For example, the proteasome subunit PSMD4 is frequently amplified 
in cases of 1q21 amplification or t(4;14) translocation [204].  Another intuitive mechanism for drug 
resistance are the upregulation of transporters that efflux chemotherapeutics out of target cells to 
confer multi-drug resistance, however it is unclear the degree to which this occurs in proteasome-
inhibitor-resistant MM [206].  
An increasingly appreciated mechanism for drug resistance in MM is the relation between 
malignant plasma cells and their bone marrow microenvironment (BMME) [207]. The BMME 
contains abundant extracellular matrix proteins (laminin, fibronectin and collagen), soluble factors 
(growth factors, cytokines, chemokines), and a host of hematopoietic and mesenchymal cells. 
When providing enough chemical growth agonists the BMME can elevate the survival capacity of 
MM cells above the level required to survive drug-induced stress. For example, exogenous IL-6 
triggers signaling through RAS/MAPK, JAK/STAT3 and PI3K/Akt pathways, all of which drive MM 
survival. This in turn prompts MM cells to secrete VEGF, a well-known driver of angiogenesis and 
a hallmark of MM progression [207]. This form of resistance would constitute a form of acquired 
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resistance where existing MM cells are supported rather than selected.  Another mechanism of 
BMME-coordinated drug resistance is through elevated cell adhesion to bonne marrow stromal 
cells (termed ‘cell-adhesion-mediated drug resistance or CAM-DR). CAM-DR is achieved via a 
host of adhesion molecules (e.g. integrins, CD44, VCAM-1 or MUC-1) [207]. These interactions 
then promote enhanced survival signaling in MM cells that are thought to be largely due to 
epigenetic remodeling [208]. 
 While exogenous factors can drive pro-survival signaling in MM to evade drug resistance, 
MM cells can also be selected for genomic aberrations that hardwire cell survival and proliferation 
despite undue stress. Two examples include loss of the tumor suppressor TP53 and the 
amplification of MYC via secondary translocations [48]. 
 
1.7 – Predictive Transcriptomic Profiling in Myeloma 
 Transcriptomic profiles that predict patient outcomes has been a long-coveted tool in 
cancer treatment. Originally explored in microarrays, next generation sequencing of cancer 
transcriptomes is slowly moving towards routine implementation as the need for personalized 
medicine approaches to cancer treatment becomes more and more apparent. The first predictive 
profiles in MM were published over 15 years ago by three MM research groups: Arkansas [209], 
IFM [210] and HOVON [211]. In theory these prognostic, directional gene expression lists could 
be applied to a patient sample transcriptomic profile to attribute them a level of prognostic risk. 
The Shaughnessy et al. publication identified a 70-gene signature (GEP70) that binned patients 
into one of seven risk categories based on gene expression and common cytogenetic 
abnormalities defined in existing sub-types [209,212].  In a normal patient group these predictions 
would put roughly 10-15% of patients at high risk. The HOVON and IFM signatures comprise of 
92 and 15 genes respectively. While procuring enough RNA for microarray studies proved 
challenging at the time, new optimization efforts have made this process much more simple and 
high-throughput. As recently reported [213], the GEP90 signature (now commercialized as 
'MyPRS®': Myeloma Prognostic Risk Score ) has been applied over 4,700 times since its 
development in 2006. Here the authors conclude that they have developed a superior technique 
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to personalize molecular characterization of MM with less subjectivity than cytogenetics/FISH 
[213]. Using transcriptomics to categorize and stratify risk for newly diagnosed MM could have 
significant utility. 
 As suggested by Szalat, Avet-Loiseau and Munshi in a recent review of MM profiling 
prospects, the ultimate goal of predictive transcriptomics should not only be to offer prognosis but 
to direct therapy [214]. The current field of MM diagnosis and treatment has yet to adopt a 
strategy where transcriptomic profiles that distinguish sensitivity and resistance to standard-of-
care therapeutics flags likely refractory individuals and directs their therapy accordingly. 
Furthermore, the recent advent of single cell transcriptomics (a technology still in its infancy), 
holds immense promise to allow sub-clonal detection of drug resistance to predict innate 
resistance and likely drug-resistant relapse. Challenges remain for mainstream adoption of these 
practices due to lack of regulatory oversight, rapidly changing therapies that outdate old gene 
expression profiles and a lack of consensus among clinicians regarding the utility of 
transcriptomic profiling [214]. 
 Some efforts to generate sensitivity and resistance profiling have been completed since 
the publication of original MM prognostic gene expression profiles. Our laboratory recently 
generated and profiled isogenic cell line pairs (Bz sensitive and resistant via progressive dose 
escalation) from a Bcl-XL/Myc double transgenic mouse model of MM [215]. The gene expression 
profile generated to distinguish Bz resistant and sensitive lines (a 23 gene signature) was 
bioinformatically queried against a host of other anti-cancer-drug-induced transcriptomic profiles. 
This query accurately predicted secondary therapies that would be uniquely efficacious in Bz 
resistant cell lines, suggesting that such profiling techniques can be effective and accurate in their 
predictions [215].  
Efforts to mine public cancer cell line gene expression datasets to generate drug 
sensitivity scores have also recently been attempted [216]. Mining public datasets can be 
informative, however these studies suffer from a lack of clinical or experimental confirmation.  
 
1.8 – Concluding Thoughts 
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 The above review of MM biology should present an extremely daunting obstacle for 
therapeutic management. Myeloma’s extreme genetic and epigenetic complexity is exemplified 
by hundreds of recurring mutations, CNVs, translocations and transcriptomic abnormalities. 
Understanding the highly intricate network of histone PTMs and their writers, readers and erasers 
presents an entirely different level of oncogenic regulation. Finally, this complex heterogeneity is 
further exacerbated by the continuous branching, sub-clonal evolution of MM. This seemingly 
paints a picture of MM where each instance is so distinct that targeting therapies based on all the 
possible covariates seems impossible.  
While some may see these obstacles as unsurmountable, the accumulation of 
information surrounding MM ‘omics’ has offered the greatest gift to researchers studying MM. As 
collecting large amounts of prognostic information (i.e. transcriptomics or whole exome 
sequence) are more often becoming a routine aspect of MM diagnosis we continue to enhance 
our understanding of how each of the many MM genomic abnormalities contributes to MM 
pathology. The new challenge in using this information to manage MM is in the development of 
new bioinformatics approaches that can accurately use patient data to direct therapies. 
 As individualizing therapy will help manage MM cases based on distinguishing 
characteristics, there is also a lot promise in applying strategies that broadly target MM. Aside 
from the exciting immunotherapies currently being explored, our understanding of MM 
epigenetics has evolved such that we now recognize broad regulatory mechanisms cancer cells 
exploit to promote a general state of persistent proliferation.  
The subtle nuances of MM biology continue to illuminate an increasingly complex 
disease. While this does present an immense challenge towards treating MM, these complexities 
also present a real opportunity to use patient data to accurately recognize specific obstacles and 
successfully treat individual cases of MM.  
 
1.9 – Statement of Thesis 
Multiple myeloma remains an incurable hematological malignancy due to the failure of 
standard-of-care therapies to broadly target a genetically diverse disease and an inability 
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overcome inevitable drug-resistant relapse. This thesis will address this outstanding problem of 
inevitable drug-resistant relapse during MM therapy by combining transcriptomic profiling to 
predict resistance to proteasome inhibitors and pre-clinical evaluation of epigenetic-targeting 
therapies to broadly target the myeloma epigenome. This document will describe two studies that 
each generate/test therapeutic strategies for overcoming heterogeneous drug response across a 
highly diverse panel of human myeloma cell lines. The first study describes an effort to 
systematically evaluate the cytotoxic profiles of a large panel of human myeloma cell lines to four 
proteasome inhibitors. We use gene expression profiles to distinguish the most and least 
resistant cell lines and from that distinction produce a weighted scoring algorithm that can predict 
extreme cases of proteasome inhibitor sensitivity or resistance. The second study evaluates new 
specific inhibitors of EZH2, a histone methyltransferase that is aberrantly active in myeloma. 
Furthermore we identify a strong synergistic potentiation of HDAC inhibition by EZH2 inhibitor 
pre-treatment and characterize the transcriptomic changes induced be each drug alone and in 
combination. These two studies represent two different approaches to overcoming drug-
resistance: one by predicting it in advance and the other by broadly targeting a core aspect of 
myeloma pathology.  
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Abstract: 
Extensive inter-individual variation in response to chemotherapy is a major stumbling block in 
achieving desirable efficacy in the treatment of cancers, including multiple myeloma (MM). In this 
study, our goal was to develop a gene expression signature that predicts response specific to 
proteasome inhibitors (PI) treatment in MM. Using a well-characterized panel of human myeloma 
cell lines (HMCLs) representing the biological and genetic heterogeneity of MM, we created an in 
vitro chemosensitivity profile in response to treatment with the four PIs Bortezomib (Bz), 
Carfilzomib (Cz), Ixazomib (Ix) and Oprozomib (Opz) as single-agents. Gene expression profiling 
was performed using next-generation high-throughput RNA-sequencing. Applying machine 
learning-based computational approaches including the supervised ensemble learning methods 
Random forest and Random survival forest, we identified a 42-gene expression signature that 
could not only distinguish good and poor PI-response in the HMCL panel, but could also be 
successfully applied to four different clinical datasets on MM patients undergoing PI-based 
chemotherapy to distinguish between extraordinary (good and poor) outcomes. Our results 
demonstrate the use of in vitro modeling and machine learning-based approaches to establish 
predictive biomarkers of response and resistance to drugs that may serve to better direct 
myeloma patient treatment options. 
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Introduction: 
Wide inter-individual variation in response to chemotherapy is a major limitation in 
achieving consistent therapeutic effect in many cancers, including multiple myeloma (MM), the 
second-most common hematologic malignancy with an estimated 30 330 new cases (~2% of all 
new cancer cases) and 12 650 estimated deaths in 2016 (NCI-SEER (The Surveillance, 
Epidemiology, and End Results program of the National Cancer Institute) Cancer statistics) [218–
221]. MM is a complex disease that can be established by a broad spectrum of genomic lesions 
and diversified by additional genomic/epigenomic abnormalities. The underlying diversity of 
disease characteristics between patients underpins the observed heterogeneity in response 
[222–224]. Heterogeneous transcriptomic profiles between patients are one of several factors 
known to contribute to the inevitable refractory/relapsing resistance to standard-of-care therapies 
[222]. Deciphering gene expression changes that can distinguish drug-sensitive and drug-
resistant myelomas is a promising approach to developing personalized chemotherapeutic 
regimens that avoids fruitless applications of common therapies.  
 Proteasome inhibitors (PIs) are among the most commonly applied standard-of-care 
chemotherapies used to manage MM. PIs are used to treat MM alone or in combination with 
alkylating agents, corticosteroids, immunomodulatory agents and histone deacetylase inhibitors 
[224–226]. Bortezomib (Bz/Btz/Velcade) was the first PI to be approved by the US Food and Drug 
Administration for clinical application in 2003 for the treatment of relapsed and refractory MM 
[227–229]. The common utilization of Bz for the treatment of MM and other cancers has spurred 
the development and testing of several second-generation PIs: Carfilzomib (Cz/Cfz/Kyprolis), 
Oprozomib (Opz) and Ixazomib (Ix/MLN9708/Ninlaro) [224,227,230].  
 Despite the positive effect Bz has had on MM median survival, MM still remains a mostly 
incurable disease (5-year survival below 50% according to NCI-SEER cancer statistics). Most 
patients undergo relapse where even patients with good initial response eventually present 
chemo-resistant disease [224]. Some recent studies have suggested that some cases of 
resistance are drug-specific where Bz-resistant MM may still be sensitive to other second-
generation PIs [225,231]. 
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 Identifying the factors that can drive resistance to PIs is a challenge. In most cases, MM 
patients receive PIs in combination with other anti-MM agents and therefore patient response 
data inherently contains diverse covariates. In addition, survival end points in clinical applications 
are measured in months to years, and hence developing prediction algorithms of response can 
be a long process.  
Despite these challenges we propose that there are transcriptomic signatures that can 
distinguish different levels of PI sensitivity/resistance. To identify such signatures, we utilized a 
collection of 50+ human myeloma cell lines (HMCLs) generated through the immortalization of 
primary MM cells that represent a broad spectrum of the biological and genetic heterogeneity of 
MM [232]. We used these HMCLs to systematically evaluate the chemo sensitivity of HMCLs to 
four PIs as single agents: Bz, Cz, Iz and Opz. This systematic evaluation produces a distribution 
of response. Cell lines that occupy the extremes of this distribution can then be selected for 
transcriptomic profiling. 
Modern transcriptomic profiles contain gene expression data for over twenty thousand 
human genes. Finding signatures within these profiles that can distinguish categorical outcomes 
is a problem well suited for machine learning based computational approaches. Generally 
machine learning approaches are ‘trained’ using large data sets each with known ‘outcomes’. 
These outcomes (the dependent variable) are either categorical (e.g. resistant or sensitive) or 
continuous (e.g. on a scale of 0.0-1.0). Training algorithms are numerous and diverse but all 
essentially randomly interrogate the data to improve correct perdition of the outcome. This 
prediction is then validated against a test data set (not used in training).  
The random forest method is possibly one of the oldest machine learning algorithms 
[233]. Random forests (RFs), as the moniker implies, are made up of many decision trees. 
Decision trees are supervised machine learning algorithms where features (tree nodes initiated at 
the root node) are selected from the data (feature space) and tested/evaluated by some criteria to 
produce a single outcome (a branch). Eventually a final conclusion/decision is reached at the 
terminal node. While individual decision trees may not be individually accurate, the consensus 
generated by all trees in a forest are what gives the random forest algorithm its designation as an 
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ensemble method for machine learning. In classification models this consensus is the mode of 
decisions and in regressive models the consensus is the mean. Additional methods can be 
applied to reduce overfitting (inflated impact of small variations in the test data) such as pruning, 
boosting and bootstrap aggregating (also known as bagging).  
Random forests can also be applied to train models that patient survival data. These data 
have unique challenges in that they are often right censored (subjects often leave studies early). 
Random survival forest (RSF) is a prediction method tailored to right censored survival data. It 
combines the random forest method with propotional hazard based models (e.g. non-parametric 
Kaplan-Meier or semi-parametric Cox propotional hazard models). Specifically relating to patient 
survival data, RSF uses Kaplan-Meier estimator for survival data as a decision tree’s terminal 
node.  
 When applied to gene expression profiling (GEP) data of MM patients from four different 
PI-based clinical trials, our GEP model of response/resistance to PIs successfully distinguished 
differences in disease progression and distinguished extraordinary (good and poor) responses. 
Thus, these results can provide a PI treatment-specific predictor of clinically relevant outcomes 
that could affect therapeutic choices. 
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Materials and Methods: 
Drugs 
Bz (Takeda Pharmaceuticals Inc., Deerfield, IL, USA) was dissolved in serum-free RPMI-
1640 (Lonza, Allendale, NJ, USA) and stored at −20 °C. Ix (Takeda), Cz and Opz (Amgen, 
Thousand Oaks, CA, USA) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, 
MO, USA) and stored at −20 °C. 
Cell lines 
Fifty HMCLs were procured from various institutions, established and characterized, and 
maintained in HMCL media with interleukin-6 [234]. Supplementary Table S1 provides the 
cytogenetic characteristics of the HMCLs. 
In vitro chemosensitivity assays 
Cell cytotoxicity assays were performed on the HMCLs to create a drug sensitivity profile 
in response to treatment with increasing concentrations of Bz, Cz, Ix and Opz as single agents 
and half-maximal inhibitory concentration (IC50) values and area under the survival curve 
(AUSC) were calculated as described earlier [234]. Briefly, cells were counted using Countess 
automated cell counter (Invitrogen, Carlsbad, CA, USA) and seeded in 96-well plates at a 
concentration of 4 × 105 cells per ml. After 24 h, cells were treated with increasing concentrations 
of Bz, Cz, Ix and Opz as single agents. Cell viability assays were performed 48 h post treatment 
using CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA) according to 
the manufacturer’s instructions using Synergy 2 Microplate Reader (BioTek, Winooski, VT, USA) 
to generate survival curves. Percent survival values were normalized to untreated controls and 
IC50 values were determined by calculating the nonlinear regression using sigmoidal dose–
response equation (variable slope). AUSC was calculated using trapezoidal rule and log2-
transformed for further statistical analysis [234]. Caspase-3/7 activity was evaluated using 
Caspase-Glo 3/7 Assay kit (Promega) on Synergy 2 Microplate Reader. 
Gene expression profiling 
RNA was isolated from six most Ix-sensitive and six most Ix-resistant cell lines and RNA 
sequencing was performed on llumina HiSeq 2000 (Illumina, San Diego, CA, USA) using 50 bp 
45 
 
paired-end protocol with depth of >20 million reads per sample. RNA-sequencing (RNA-seq) data 
from CD138-selected plasma cells were generated from MM patients enrolled in an ongoing 
phase-2 Ixazomib clinical trial at Mayo Clinic (Mayo-Ix; NCT01415882) that enrolled patients with 
relapsed myeloma who had less than six cycles of prior treatment with a Bz-based regimen and 
were not refractory to Bz [235]. High quality RNA was extracted from HMCLs using QIAshredder 
and RNeasy kit (Qiagen). RNA concentration and integrity were analyzed using the Nanodrop-
8000 and Agilent 2100 Bioanalyzer and stored at -80°C. RNA integrity number/RIN>8 was 
considered suitable for RNA-seq analysis. RNA-seq library construction was performed using the 
Illumina TruSeq RNA sample Preparation kit v2. The libraries were size selected to generate 
inserts of ~200bp and RNA sequencing was performed using llumina’s HiSeq 2000 next-
generation high-throughput sequencing system using 50bp paired-end protocol with depth of 
>20million reads-per-sample. Average quality scores were well above Q30 for all libraries in both 
R1 and R2. Data was normalized and FPKM values were used in further analysis using a 
combination of Galaxy data analysis software and Partek Genomics Suite. GEP vs in vitro 
chemo-sensitivity data was then used to identify gene expression signatures associated with PI 
response. 
Gene expression data was pre-processed using Galaxy, an open source, web-based 
platform that provides tools necessary to create and execute RNA-seq analysis. Briefly, an RNA-
seq data analysis pipeline was developed using Galaxy that performs quality control (QC) check 
on the RNA-seq raw reads using FastQC tool, trims the reads to remove base positions that have 
a low median (or bottom quartile) score and then uses Tophat2 tool to map processed RNA-seq 
reads to the hg19 human genome build. Estimated insert sizes were derived using Picard's 
CollectInsertSizeMetrics tool on this initial tophat2 run which was used to calculate mean inner 
distance between mate pairs (Mean= estimated_insert-size - 2*read_length).  Tophat2 was then 
re-run using correct mean value and finally Cufflinks tool was used on these datasets to 
assemble the reads into transcripts. 
Prior to analysis, the processed transcripts were filtered using the following criteria: genes with 
variance=0, FPKM<1 and mean FPKM<5 were removed. 
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Gene expression, treatment arm and outcome data on newly diagnosed myeloma 
patients enrolled in HOVON65/GMMG-HD4 trial (ISRCTN64455289; n=290) were downloaded 
from Gene expression omnibus (GEO) (GSE19784) [211]. The APEX data set (GSE9782; n=264) 
consists of bortezomib-based phase-2 and phase-3 relapsed and/or refractory myeloma clinical 
trials (The APEX phase-3 trial (039), a companion study (040), the SUMMIT (025) and CREST 
phase-2 trials (024)) [236]. For both these trials, Affymetrix, Santa Clara, CA, USA gene probe set 
analysis data (U133-Plus2.0 for HOVON65/GMMG-HD4 and HG-U133A/B for APEX) were 
available. Pretreatment RNA-seq data, treatment arm and clinical outcome information on 
CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) trial 
patients were downloaded from the MMRF (Multiple Myeloma Research Foundation) researcher 
gateway portal (IA7c release; https://research.themmrf.org). The CoMMpass Trial (NCT0145429), 
sponsored by MMRF, is a non-registrational, longitudinal study of 1000 newly diagnosed MM 
patients followed over the course of their disease, up to 8 years.20 
Bioinformatics and statistical analysis 
All statistical analyses were performed using R software environment (https://www.r-
project.org/) version 3.3.1 for statistical computing and graphics, and GraphPad Prism v7.0 
(GraphPad Software, Inc., La Jolla, CA, USA). Spearman’s rank-order and Pearson’s product-
moment correlation analyses were performed to compare the PI responses. All tests were two 
sided and P<0.05 was considered statistically significant. Gene expression data were 
preprocessed, log2-transformed and analyzed using Galaxy and Partek Genomics Suite v6.6 
(Partek Inc., St Louis, MO, USA) to perform differential expression testing to identify gene 
expression signatures PI response (details above). Analysis of variance model or two-sided 
paired sample t-test was used to evaluate whether each gene is differentially expressed. 
Heatmaps were generated using unsupervised hierarchical clustering analysis based on the 
differentially expressed genes. 
Supervised machine learning approaches construct algorithms that learn from training 
data, build models based on properties of training inputs and thus make learned 
predictions/decisions on new/test samples [233,234]. Random forest, a supervised ensemble 
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machine learning algorithm, was used to establish the top differentially expressed genes as 
predictive GEP signatures of PI response [233]. GEP data on top Ix-sensitive vs top Ix-resistant 
HMCLs (n=12) were used as ‘training data set’ to build random forest classification models 
(decision trees) and predict PI resistance of HMCLs (n=44) in the ‘test data set’, the mRNA-seq 
data obtained from the Keat’s lab repository (http://www.keatslab.org/data-repository). The 
average bootstrap prediction error was generated using repeated bootstrapping of the train data 
set with a k-fold cross-validation (k=100). The cross-validation error rate was used to evaluate the 
accuracy of the method [233,234]. 
The predictive GEP signature was then applied to the four different PI-based MM clinical 
trials and random survival forest estimation method for right censored data (randomForestSRC R 
package), another supervised machine learning decision-tree based algorithm, was used to 
predict probability of progression/event (0=censored; 1=progression) within the first 3 years for 
each myeloma patient [237]. The predicted probability values derived using machine learning 
approaches (random forest and randomForestSRC) were rank-ordered and the predictions for the 
top (Q3) and bottom quantiles (Q1) were compared with observed PI response using Somers’ 
Dxy rank correlation [238] (see full details in Supplementary Methods available online [217]). 
Unsupervised K-means clustering was performed using the algorithm of Hartigan and 
Wong [239] to identify clinically important K-subgroups based on our PI response GEP signature 
such that N/K~30 (N=total number of subjects in data set). Kaplan–Meier curves for survival were 
generated for the extraordinary PI response (good vs poor) clusters by computing progression-
free survival (PFS) over time [240] The Kaplan–Meier survival curves were compared statistically 
using log-rank test and Cox proportion hazard test [241]. Clusters with n<10 were combined for 
PFS comparisons. 
Odds ratios (ORs) between observed clinical responses (available for APEX and 
CoMMpass data sets) vs extraordinary PI-response K-means clusters were computed using 
binomial logistic regression analysis (logit model) [242]. 
Ingenuity pathway analysis 
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The differentially expressed genes were analyzed using Ingenuity Pathway Analysis 
(IPA) to identify canonical pathways, downstream effects, upstream regulators and causal 
networks and to perform predictive toxicology analysis using toxicogenomics approaches (IPA-
Tox) [243]. 
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Results: 
Wide variability in response to PI treatment 
 We used a large panel of HMCLs as a model to recapitulate the genomic heterogeneity 
between MM patients. We systematically measured the in vitro sensitivity of 50 HMCLs to four 
PIs (Bz, Cz, Ix and Opz). Doses were consistent between cell lines and cell viability after 48hrs 
was measured using a CellTiter-Glo® (Promega) assay. Cytotoxicity in these assays was further 
confirmed with caspase-3/7 cleavage assays (data not shown). We compared sensitivity across 
cell lines using two metrics: IC50 and area under the survival curve (AUSC). IC50 is the dose that 
produces 50% viability after the specified treatment time (48hrs) and AUSC normalizes the area 
under the survival curve (trapezoidal method) to a total lack of response (i.e. max dose multiplied 
by 100% viability). These data identified a distribution of responses to PIs where, as in patient 
populations, some PIs respond to low doses of PIs while others are relatively resistant (Figures 
1a and 1b). In some cases AUSC was a better comparative method as some HMCLs displayed 
PI-resistance to the point of not achieving an IC50 value. The summary of cytotoxic analysis 
across all four PIs (Table 1) articulates the magnitude at which responses vary between HMCLs. 
Generally all four PIs demonstrated similar distributions across the HMCL panel as demonstrated 
in a correlation matrix between PI IC50’s and AUSCs (Figure 1c). Correlation was statistically 
significant across all four PIs (Holm’s method adjusted p-values all <0.001).  
We did find some instances where HMCLs showed sensitivity to one PI and resistance to 
another. This further suggests that some tumors that are refractory to one PI may still respond to 
another. 
Importantly, response was similar between all PIs at the top and bottom of the response 
distribution (exceptionally high/low response), allowing us to attempt to characterize 
transcriptomic differences between these extremes. 
 
Deriving a GEP-based signature profile of PI response 
We performed differential gene expression analysis between 5 (top 10%) most Ix-sensitive and 5 
(bottom 10%) most Ix-resistant cell lines. Notably, these cell lines showed the same relative 
50 
 
sensitivity and resistance to all four proteasome inhibitors. RNA was isolated from these cell lines 
(untreated) and subjected to RNA-sequencing (RNA-seq) and subsequent data processing and 
analysis. Prior to analysis, the processed transcripts were filtered using the following criteria: 
genes with variance=0, FPKM<1 and mean FPKM<5 were removed. Differential gene expression 
analysis was performed using the remaining 7682 genes to identify GEP signatures that 
distinguish the highly sensitive from the highly resistant HMCLs. Results showed 506 genes 
differed significantly between the sensitive and the resistant groups (P<0.05; fold change ≠1). In 
all, 141 genes showed |fold change| >2 and P<0.05, whereas 42 genes, listed in Table 2, had 
P<0.01 (|fold change| >2) (Figure 2). Subsequent analyses used the more stringent highly 
variable/differentially expressed 42-gene list. 
 
GEP signature of PI response is predictive of in vitro PI chemosensitivity in HMCLs and 
progression in MM clinical trials 
Our experimental approaches yielded a 42-gene signature that distinguished extreme 
sensitivity and extreme resistance within our HMCL panel. We sought to determine the predictive 
capacity this signature bears outside this context. We elected to utilize machine-learning 
computational approaches to further enhance the predictability of our signature using publically 
available data. Supervised machine learning approaches construct algorithms that learn from 
training data, build models based on properties of training inputs and thus make learned 
predictions/decisions on new/test samples. The training data set comprised gene expression 
profiles of HMCLs that represent extremities of PI responses, whereas the initial validation/test 
data set was derived from an independent gene expression study on HMCLs (n=44) performed in 
the Keats laboratory at TGen laboratories (http://www.keatslab.org/data-repository). The final 
validation data set of human myeloma patients comprised four independent clinical trials 
(HOVON65/GMMG-HD4 (n=290); APEX (n=264); CoMMpass (n=765); and the Mayo-Ix trial 
(n=22)). 
First, the random forest algorithm for classification was ‘trained’ using mRNA-seq data on 
the 42-gene signature from 6 most PI-sensitive and 6 most PI-resistant cell lines. The out-of-bag 
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estimate, which is a measure of mean prediction error of the training model calculated by 
subsampling the training data set, was computed as 0%. Concurrently, the classification error 
rate derived from confusion matrix was also 0, thus validating the robustness of the training 
model. Supplementary Figure S1 provides the gene importance plot representing the most 
important genes within the 42-gene expression signature influencing PI response based on 
variable importance (VIMP) measure derived from random forest analysis. 
The probability scores of PI resistance were then calculated for each of the HMCLs 
obtained from the Keatslab data repository (‘test’ data set). The predicted probabilities of PI 
resistance were then rank-ordered and Somers’ Dxy rank correlation analysis was performed 
between the top quantile (Q3) and bottom quantile (Q1) resistance probability values and 
observed PI chemosensitivity as a binary outcome (sensitive=0 vs resistance=1). Results 
revealed high positive Somers Dxy rank correlation for the PI drug cytotoxicity parameters (IC50 
and AUSC) (Table 3), indicating that our 42-gene GEP signature validated quite well in an 
independent data set of HMCLs. 
As the classification model was generated using HMCLs with top-6+bottom-6 Ix IC50 
values as training data set, the test data set for Ix IC50 prediction included RNA-seq data on the 
remaining 32 cells lines only from an independent data set obtained from the Keatslab repository. 
Among these, Somers’ c value for correlation between observed Ix IC50 and response 
probabilities of the top 6 predicted Ix-resistant cell lines was 0.667 whereas it was 1.0 for the top 
6 predicted Ix-sensitive lines. Somers’ c for the combined set of 12 predicted sensitive+resistant 
HMCLs was 0.743. Thus, the independent cell line test set showed very good correlation with the 
signature-derived predictor. 
 Although the training set showed good prediction capabilities in an independent set of 
HMCLs, we were particularly interested to determine whether it is able to stratify patient 
outcomes in multiple clinical trials. Four different PI-treating trials were examined (treatment 
details provided in Materials and Methods). Microarray gene expression data from clinical trials 
was mean-centered and scaled before analysis. The standardized transcriptomic profiling data 
from APEX trial was used as a training data set to perform random survival forest analysis to 
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predict the percent probability of a progression/event within 3 years in the HOVON-GMMG-HD4, 
CoMMpass and Mayo-Ix clinical trials (test data sets). Somers’ Dxy rank correlation analysis 
between the top and bottom quantiles of predicted percentage values from random survival forest 
model on test data and the progression index of the test data sets showed consistent positive 
values for the HOVON-GMMG-HD4, CoMMpass and Mayo-Ix clinical trials revealing high 
prediction accuracy of the random survival forest-based prediction model [237,238] (Table 4). 
Somers’ c for the training data set (APEX) was=0.852. 
 As we were particularly interested in our signature’s drug response performance, we 
chose to look at progression as one measure of response/nonresponse as well as associations 
that distinguish clinical definition of response, complete response versus nonresponse [244]. K-
means clustering is a computational method for clustering datasets (e.g. patient sample 
transcriptomes) into a user defined number of clusters. K-means clustering was performed on 
188 MM patients from the Bz treatment arm of the APEX data set19 to partition the samples into 
clusters/subgroups based on the expression of the 42 genes comprising the GEP signature of PI 
response. Results show significant differences in PFS between the signature-derived poor PI-
response and good PI-response groups (hazard ratio (HR)=2.346; P=0.0076; Figure 3a). 
Conversely, no difference in PFS is observed between the K-means clusters when the 42-gene 
model was applied to the expression data of 76 patients in the dexamethasone arm of APEX 
phase-3 trial that compared single-agent Bz with high-dose dexamethasone (HR=1.1; P=0.732; 
Figure 3a), showing our GEP signature is drug-specific. Concurrently, statistically significant 
association is observed between the K-means clusters and clinical response in the Bz arm 
(ORresponder vs nonresponder=5.813; 95% confidence interval=1.833–20.007; POR=0.0036) 
but not in the Dex arm (ORresponder vs nonresponder=2.139; 95% confidence interval=0.753–
6.326; POR=0.158) of the APEX data set. 
 When applied to the gene expression data from HOVON-GMMG-HD4 clinical trial 
(n=290) that implemented a Bz-based drug regimen [211], the 42-gene signature shows 
statistically significant differences in PFS among K-means clusters representing good vs poor PI 
response in the Bz-treated PAD (bortezomib, doxorubicin and dexamethasone) arm (HR=2.161; 
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P=0.024), whereas no difference in PFS is observed in the VAD (vincristine, doxorubicin and 
dexamethasone) arm (HR=1.282; P=0.437; Figure 3b). What is particularly striking is that within 
the first 1.5 years the predicted good response group in the PI-containing therapy had no 
progression events, whereas 35% of the predicted poor response group had progression events. 
 Clinical data were available on 765 patients from the CoMMpass study. A total of 253 
patients used Bz as first-line therapy, alone or in combinations. Of these, 128 had RNA-seq and 
PFS data available. K-means clustering based on the expression of the 42 genes distinguishes 
between good and poor PFS subgroups of myeloma patients (HR=2.556; P=0.0277; Figure 3c). 
In addition, the K-means clusters are also found associated with clinical response (OR=5.20; 95% 
confidence interval=1.22 36.077; POR=0.0453). In contrast, among the 96 patients using 
Lenalidomide (an immuno-modulatory drug) as first-line therapy, no association was observed 
between the good and poor K-means clusters and PFS (P=0.49; Figure 3c). Our results thus 
further validate the PI response specificity of our method. 
 Finally, we applied our algorithm based on the our 42-gene PI response signature to an 
ongoing clinical trial at Mayo Clinic that uses Ix-containing drug regimen. Interestingly, even with 
small numbers of patients available, our GEP-based PI response classifier distinguishes between 
the top (medium PFS=22.42 months) and bottom responders (medium PFS=12 155 months) in 
this Ix trial (risk ratio=2.5) (Figure 3d). Notably, all 10 patients in the good performance group 
were alive at the latest point of the interim analysis, whereas 4 out of 9 patients in the poor PI 
response cluster died (inset of Figure 3d). 
Ingenuity pathway analysis 
 We subjected our 42-genes to network analysis to determine if this signature was 
particularly enriched for any specific biological pathways. Ingenuity Pathway Analysis (IPA)[245] 
is a network analysis platform that can be queried with gene expression changes and return 
enriched network information from the QIAGEN knowledge base. Out of the 42 genes, 12 
overlapped with the top IPA network obtained from the analysis of direct and indirect relationships 
(score=26), as represented in Supplementary Figure S2a. Genes/molecules in this network 
include the 26s proteasome complex. Furthermore, when we used the IPA upstream regulator 
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analysis, TFEB and CCND1 were identified as the top hits/factors that may control the genes and 
pathways highlighted by network analysis (Supplementary Figure S2b). The functional 
significance is discussed further in the Discussion. 
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Discussion: 
 MM remains an incurable disease primarily due to the inability of current standard-of-care 
to treat effectively treat MM. Patients who are not already refractory to anti-MM chemotherapies 
will almost always develop drug-resistant relapse. This strongly supports the need for predictive 
methods that identify cases of extreme innate drug-resistance.  
 Differential gene expression signatures have been developed for MM [211,232,246], 
however these signatures were designed to stratify patients based on prognosis and none of 
those signatures were treatment specific. Furthermore, no study thus far has made use of the 
vast array of HMCLs as model system to generate drug chemosensitivity profile as a 
representation of the response variation in patient subtypes that may be used to derive a PI-
specific GEP signature predictive of resistance and treatment outcomes. 
 In this study, we successfully used a panel of 50 HMCLs to model heterogeneous 
response to PIs within a gnomically diverse population. All four PIs had distributions of sensitivity 
that was highly correlated across the panel. Some outliers were noted.  Interestingly, several cell 
lines with intermediate response to Bz or Ix were found highly responsive to Cz treatment. 
However, in general the ranked correlation with response was very similar among all four PIs, 
particularly those lines that were collectively the most responsive and least responsive to all four 
PIs (extraordinary responders). Further characterization of the outliers may reveal important 
features that better direct which PI is most effective. 
 Having established this chemosensitivity distribution among HMCLs we focused on 
identifying common transcriptomic differences between highly sensitive and highly resistant 
HMCLs. RNA-seq analysis and stringent thresholding produced our 42-gene signature that 
represents those transcriptomic differences. Importantly, this signature was not applied across 
the full range of responses, but was very effective in identifying extraordinary (good versus poor) 
response. 
 Several of the genes identified in our GEP have known connections to the ubiquitin 
proteasome system and endoplasmic reticulum (ER) stress. IPA WFS1, a cation-selective ion 
channel embedded in the ER, plays a role in ER stress (a direct consequence of inhibiting protein 
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turnover at the proteasome) [247]. Furthermore, WFS1 is downstream from the transcription 
factor XBP-1, which is also noted to be directly involved in ER-stress induced apoptosis [248]. 
This may be, in part, why high XBP-1 expression is a good prognostic marker for MM [248,249]. 
Interestingly, we found that the unspliced transcript of XBP1 (Xbp1u) had ~1.5 times lower 
expression in Ix-resistant cell lines when compared with Ix-sensitive cell lines. The transcription 
factor EB (TFEB) is a master gene for lysosomal biogenesis that ultimately facilitates autophagy 
cell death. While  this may be a path to cell-death in MM it is also notable that lysosomal 
clearance of aggresomes is a means to tolerate PI-induced ER stress [250]. RNF170 encodes an 
ER membrane ubiquitin ligase that mediates ubiquitination and degradation and plays a key role 
in cell signaling [251]. 
 While many of these genes seemingly have no connection to the proteasome and its 
related pathways, several genes included in our GEP signature have been previously implicated 
with prognosis and disease progression in myeloma. For example, CCND1, the gene encoding 
cell cycle regulator cyclin D1, is frequently misregulated in MM. CCND1 has additionally been 
reported to be a strong prognostic indicator [232,234]. HSPA1B is an NRF2-mediated oxidative 
stress response gene that was also identified in a previous study of ours screening for 
transcriptomic markers of Bz sensitivity/resistance in a murine model of MM [215]. Gla, a 
metabolic enzyme, has been shown to play a role in regulating bone resorption in MM [252].  
 We used this 42-gene signature to train ensemble machine learning methods, thereby 
further assessing the predictability of this signature outside the context in which it was generated. 
We first used RF methods to train models using our HMCL transcriptomic data and test with 
transcriptomic data generated in a separate laboratory.  
While the number of cell lines used to generate our 42-gene signature was relatively 
small, when applied to clinical trial data, it was remarkably predictive of extraordinary PI 
sensitivity/resistance. RSF methods, when trained using clinical trial data demonstrated 
consistent correlations with outcomes in test data sets. Using our signature to K-means cluster 
clinical trial cohort’s accurately segregated patients treated with PIs into different outcomes. 
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Encouragingly, this was not observed in clinical trial arms that did not contain PIs in the treatment 
regimen.  
Earlier, we demonstrated that gene expression signatures may be used to identify 
secondary therapies in PI-resistant MM using in silico predictions that were confirmed in vitro 
[215,253]. In 2014, the NCI initiated the Exceptional Responders Initiative to understand the 
molecular basis of exceptional response to chemotherapy in cancer patients enrolled in clinical 
trials [254]. The primary goal of the study is to identify molecular features in malignant tissue that 
may aid to predict response to same or similar drugs. On similar lines, our work should serve as 
resource to use machine learning-based approaches for the personalized prediction of 
exceptional chemoresistance and to eventually identify signatures of drug combination regimens 
that may effectively reverse drug resistance by predicting drugs for various 
subpopulations/subclones of tumors based on pharmacogenomic signature profiles. 
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Figure Legends: 
 
Figure 1. In vitro chemo-sensitivity profiles of human myeloma cell lines following proteasome 
inhibitor treatment. 
 
a) Plots show survival compared to untreated control versus increasing concentration of 
bortezomib, oprozomib, ixazomib, carfilzomib. In b) the Area Under the Survival Curve (AUSC) 
was normalized and expressed as percentage of the largest value for each drug, shown for all 
cell lines treated with the four proteasome inhibitors. In c) the Scatterplot matrix is shown as a 
pairwise correlation of the natural log (Ln) of IC50 and AUSC values for the response to each PI 
drug. Scatterplot matrix was generated using the R graphing package ggplot2. 
 
Figure 2. Heat map representing differential gene expression between PI-sensitive vs PI-
resistant myeloma cell lines. 
 
Gene expression was z-score normalized (standardized: shifted to mean of 0 and scaled to 
standard deviation of 1) and compared among the 5 most Ix-responsive and 5 least Ix-responsive 
cell lines. Heatmap was generated using the top 42 differentially expressed genes (|fold-
difference|>2; p<0.01). Columns are ordered by Ix IC50 of cell; genes are ordered by fold-
difference. Color indicates fold-change between Ix-resistant vs Ix-sensitive cell lines. 
 
Figure 3. Plots showing stratification in progression-free survival (PFS) among MM patients on 
PI-based clinical trials in which the 42-gene model was used to assign extraordinary (good and 
poor) PI-response. 
 
Kaplan-Meier survival curves in a) APEX dataset: bortezomib arm shows significant separation of 
PFS between clusters representing good vs poor outcomes; whereas the dexamethasone arm 
shows no stratification; b) patients in the HOVON-GMMG-HD4 trial (Bz-treated/PAD and VAD 
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arms) were assigned good versus poor PI-response based on the 42 gene model. PFS curves for 
the interim analysis of the c) CoMMpass trial (NCT0145429) patients administered Bz or 
Lenalidomide (Len) as first line of therapy, and d) the Mayo Clinic Ix-trial (NCT01415882). 
Patients were assigned good versus poor response based on the 42-gene model. Inset of 3d) 
shows survival of each patient considered. Dashed line represents end of year 1 (365.25 days 
from randomization). 
 
Figure S1: Gene importance plot derived from Variable/ Feature selection using machine 
learning on the training dataset.  
 
MeanDecreaseGini is the measure of gene importance for training dataset. 
 
Figure S2. Ingenuity Pathway analysis showing the prediction of the a) top network and b) top 
upstream regulator based on the 42-gene signature of PI-response.  
 
Gene nodes are displayed using various shapes denoting the functional class of the gene 
product. Green symbolizes downregulation of gene expression, while red represents upregulation 
of gene expression. The significance of up/down-regulation is represented by color intensity. 
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Table 1. Numerical summaries of chemo-sensitivity parameters in HMCLs 
Proteasome inhibitor Mean (nM) Minimum (nM) Median (nM) 
Maximum 
(nM) 
Bortezomib_ IC50 17.1 2.8 11.7 124.3 
Carfilzomib_ IC50 10.9 0.7 7.1 55.3 
Ixazomib_ IC50 155.3 15.1 42.1 4757.9 
Oprozomib_ IC50 45.8 7.6 23.7 776.0 
     
Bortezomib_ AUSC 2700.1 319.6 1524.0 38974.0 
Carfilzomib_ AUSC 3503.4 375.5 1448.5 19097.0 
Ixazomib_ AUSC 10030.0 1702.0 6456.0 46494.0 
Oprozomib_ AUSC 5017.0 1050.0 2885.0 59917.0 
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Table 2. List of genes most significantly associated with PI resistance (|Fold-difference| > 2; p < 
0.01) 
 
Differential gene expression analysis was performed to compare gene expression profiles of 5 
(Top 10%) most Ix-sensitive and 5 (Bottom 10%) most Ix-resistant cell lines. These 42 genes 
were used as GEP signature of PI resistance to stratify PI response in test datasets (in vitro and 
among patients).  
 
# Gene ID p-value 
Fold-difference 
(Sensitive vs. 
Resistant) 
Fold-difference  
(Description) 
1 SLC1A4 0.00004 2.695 Sensitive up vs Resistant 
2 NEK3 0.00006 -2.544 Sensitive down vs Resistant 
3 GLA 0.00007 2.073 Sensitive up vs Resistant 
4 AKNA 0.00020 4.043 Sensitive up vs Resistant 
5 ARHGAP27 0.00035 3.599 Sensitive up vs Resistant 
6 LY96 0.00045 3.796 Sensitive up vs Resistant 
7 DLST 0.00070 -2.001 Sensitive down vs Resistant 
8 MSL3 0.00132 2.237 Sensitive up vs Resistant 
9 SQRDL 0.00134 3.906 Sensitive up vs Resistant 
10 NCAPH2 0.00206 2.129 Sensitive up vs Resistant 
11 PLK1S1 0.00262 -2.035 Sensitive down vs Resistant 
12 MRI1 0.00284 2.448 Sensitive up vs Resistant 
13 TARS2 0.00294 -2.083 Sensitive down vs Resistant 
14 OBFC2A 0.00307 3.756 Sensitive up vs Resistant 
15 RAB8A 0.00319 2.097 Sensitive up vs Resistant 
16 ABHD2 0.00363 2.475 Sensitive up vs Resistant 
17 LMF2 0.00364 2.558 Sensitive up vs Resistant 
18 C6orf48 0.00367 -2.462 Sensitive down vs Resistant 
19 TUBA4A 0.00400 2.189 Sensitive up vs Resistant 
20 HSPA1B 0.00467 -2.335 Sensitive down vs Resistant 
21 TFEB 0.00471 -2.302 Sensitive down vs Resistant 
22 RNF170 0.00504 -2.34 Sensitive down vs Resistant 
23 SOX12 0.00569 -2.281 Sensitive down vs Resistant 
24 ZNFX1-AS1 0.00604 -2.482 Sensitive down vs Resistant 
25 C2orf69 0.00622 2.038 Sensitive up vs Resistant 
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26 PTPN18 0.00634 2.635 Sensitive up vs Resistant 
27 PRKD2 0.00641 3.5 Sensitive up vs Resistant 
28 KHK 0.00662 2.484 Sensitive up vs Resistant 
29 PAQR6 0.00710 -3.645 Sensitive down vs Resistant 
30 HIST1H2BD 0.00763 -4.514 Sensitive down vs Resistant 
31 CERK 0.00776 2.481 Sensitive up vs Resistant 
32 UBE2K 0.00806 -2.048 Sensitive down vs Resistant 
33 LYSMD1 0.00814 -2.379 Sensitive down vs Resistant 
34 GPSM3 0.00832 5.309 Sensitive up vs Resistant 
35 MNAT1 0.00906 -2.144 Sensitive down vs Resistant 
36 WFS1 0.00911 2.397 Sensitive up vs Resistant 
37 MYH9 0.00923 2.011 Sensitive up vs Resistant 
38 CYTIP 0.00925 2.855 Sensitive up vs Resistant 
39 SVIP 0.00928 2.148 Sensitive up vs Resistant 
40 ARSA 0.00931 3.3 Sensitive up vs Resistant 
41 SFMBT2 0.00947 2.111 Sensitive up vs Resistant 
42 POLR3GL 0.00958 -2.251 Sensitive down vs Resistant 
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Table 3. Summary of correlation between predicted probabilities of PI-resistance vs observed PI 
cytotoxicity values 
 
Random forest classification model was generated using HMCLs with top-6 + bottom-6 Ix-IC50 
values as training dataset. Predicted probability values of HMCLs in the test dataset were rank-
ordered and Somers’ Dxy rank correlation analysis was performed between the top quantile/Q3 
and bottom quantile/Q1 resistance probability values observed PI-chemosensitivity as a binary 
outcome (sensitive=0 vs resistance=1). Spearman rank-ordered correlation was performed in cell 
lines representing Q3 and Q1 probabilities of resistance and corresponding cytotoxicity values. 
 
 Somers' c Spearman's rho 
  cQ3 cQ1 CQ3+Q1 SpearmanQ3+Q1 P 
Bz_IC50 0.643 0.786 0.852 0.748 0.00036 
Cz_IC50 0.714 0.524 0.750 0.563 0.00981 
Opz_IC50 0.667 0.944 0.802 0.626 0.00548 
            
Bz_AUSC 0.643 0.786 0.852 0.736 0.00050 
Cz_AUSC 0.595 0.667 0.712 0.601 0.00507 
Ix_AUSC 0.857 0.889 0.927 0.765 0.00009 
Opz_AUSC 0.667 0.786 0.813 0.630 0.00509 
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Table 4. Summary of Somers’ Dxy rank correlation analysis between predicted probability values 
of progression (derived from random survival forest model) and the progression index of MM 
patients from PI-based clinical trials (test datasets) 
 
Transcriptomic profiling data from APEX trials was used as training dataset. 
 
  Somers' c 
  cQ3 cQ1 CQ3+Q1 
HOVON-GMMG-HD4 (PAD Arm) 0.596 0.599 0.561 
CoMMpass – Bz First-line therapy 0.705 0.469 0.595 
CoMMpass – Len First-line therapy 0.320 0.203 0.262 
Mayo-Ix 0.500 0.833 0.680 
APEX-Dex Arm 0.365 0.467 0.431 
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Table S1. List of Human Myeloma Cell Lines (HMCLs) included in this study 
 
Translocations and cyclin D expression (TC)-based classification system- 4=4;14 translocation 
involving MMSET/FGFR3; 11/6/12=Cyclin D1/3/2 IgH translocation; M = MAF.IgH; M.L,M.K 
&M.0=rearrangement with IgL,IgK, or no Ig; D2 = CYCLIN D2 expression without primary IgH 
TLC; 0 = no  Ig TLC; low expression of all 3 Cyclin D genes 
Cell lines Number of Chromosomes 
Translocations and cyclin D 
expression (TC)-based classification 
system 
TC 
Group 
code 
H929 45 4;14 translocation involving MMSET/FGFR3 4 
JIM3 61 4;14 translocation involving MMSET/FGFR3 4 
Kas6/1 70 4;14 translocation involving MMSET/FGFR3 4 
KMS18 74 4;14 translocation involving MMSET/FGFR3 4 
KMS26 75 4;14 translocation involving MMSET/FGFR3 4 
KMS28PE 43 4;14 translocation involving MMSET/FGFR3 4 
KMS34 71 4;14 translocation involving MMSET/FGFR3 4 
LP1 80 4;14 translocation involving MMSET/FGFR3 4 
OPM1 74 4;14 translocation involving MMSET/FGFR3 4 
OPM2 74 4;14 translocation involving MMSET/FGFR3 4 
PE2 72 4;14 translocation involving MMSET/FGFR3 4 
UTMC2 77 4;14 translocation involving MMSET/FGFR3 4 
XG7 43 4;14 translocation involving MMSET/FGFR3 4 
KMM1 80 Cyclin D3 IgH translocation 6 
FLAM76 42 Cyclin D1 IgH translocation 11 
H1112 46 Cyclin D1 IgH translocation 11 
Karpas620 68 Cyclin D1 IgH translocation 11 
KMS12BM 77 Cyclin D1 IgH translocation 11 
KMS12PE 77 Cyclin D1 IgH translocation 11 
MMM1 47 Cyclin D1 IgH translocation 11 
MOLP8 86 Cyclin D1 IgH translocation 11 
OCIMY7 78 Cyclin D1 IgH translocation 11 
SKMM2 37 Cyclin D1 IgH translocation 11 
U266P/VR 39 Cyclin D1 IgH translocation 11 
XG1 44 Cyclin D1 IgH translocation 11 
AMO1 75 Cyclin D2 IgH translocation 12 
DELTA47 45 CYCLIN D2 expression without primary IgH TLC D2 
FR4 100 CYCLIN D2 expression without primary IgH TLC D2 
JK6L 50 CYCLIN D2 expression without primary IgH TLC D2 
KHM1B 59 CYCLIN D2 expression without primary IgH TLC D2 
KMS20 41 CYCLIN D2 expression without primary IgH TLC D2 
KP6 47 CYCLIN D2 expression without primary IgH TLC D2 
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MOLP2 NA CYCLIN D2 expression without primary IgH TLC D2 
OCIMY1 49 CYCLIN D2 expression without primary IgH TLC D2 
ANBL6 82 MAF.IgH translocation M 
ARD 48 MAF.IgH translocation M 
ARP1 48 MAF.IgH translocation M 
ARP11c 48 MAF.IgH translocation M 
JJN3 60 MAF.IgH translocation M 
MM1S/VR 44 MAF.IgH translocation M 
OCIMY5 46 MAF.IgH translocation M 
SACHI 42 MAF.IgH translocation M 
SKMM1 79 MAF.IgH translocation M 
L363 46 No Ig rearrangement M_0 
KMS11 70 MAF.IgH translocation; 4;14 translocation involving MMSET/FGFR3 M_4 
RPMI8226 60 rearrangement with IgL, M_L 
XG2 49 rearrangement with IgL, M_L 
XG6 77 rearrangement with IgL, M_L 
 
  
68 
 
FIGURE 1 
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FIGURE 1 continued 
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FIGURE 2 
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FIGURE 3 
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FIGURE S1 
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FIGURE S2 
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Abstract:  
Multiple myeloma (MM) remains a largely incurable hematologic cancer due to an inability to 
broadly target inevitable drug-resistant relapse. Epigenetic abnormalities are abundantly present 
in multiple myeloma and have increasingly demonstrated critical roles for tumor development and 
relapse to standard therapies. Accumulating evidence suggests that the histone 
methyltransferase EZH2 is aberrantly active in MM. We tested the efficacy of EZH2 specific 
inhibitors in a large panel of human MM cell lines (HMCLs) and found that only a subset of 
HMCLs demonstrate single agent sensitivity despite ubiquitous global H3K27 demethylation. Pre-
treatment with EZH2 inhibitors greatly enhanced the sensitivity of HMCLs to the pan-HDAC 
inhibitor panobinostat in nearly all cases regardless of single agent EZH2 inhibitor sensitivity. 
Transcriptomic profiling revealed large-scale transcriptomic alteration by EZH2 inhibition highly 
enriched for cancer-related pathways. Combination treatment greatly increased the scale of gene 
expression change with a large portion of differentially expressed genes being unique to the 
combination. Transcriptomic analysis demonstrated that combination treatment further perturbed 
oncogenic pathways and signaling nodes consistent with an antiproliferative/pro-apoptotic state. 
We conclude that combined inhibition of HDAC and EZH2 inhibitors is a promising therapeutic 
strategy to broadly target the epigenetic landscape of aggressive MM. 
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Introduction:  
Multiple myeloma (MM), a hematopoietic malignancy with over 30,000 new cases each 
year in the United States, is characterized by clonal expansion of malignant post-germinal-center 
B-cell-derived plasma cells within the bone marrow [3]. While current therapies including 
proteasome inhibitors and immunomodulatory drugs have improved disease management, MM 
remains largely incurable [231]. Heterogeneous patient response to therapy and the inevitable 
emergence of drug-resistant relapse impede long-term therapeutic efficacy. This illustrates the 
need for new therapeutic strategies that improve the efficacy of current compounds and more 
broadly target malignant plasma cells.  
Epigenetic abnormalities are abundantly present in multiple myeloma (MM) and have 
increasingly demonstrated critical roles for tumor development and resistance to therapy 
[77,57,255,58,256]. Therapeutic strategies that target epigenetic modifiers have recently gained 
momentum in many cancers including recent FDA approval for the pan-HDAC inhibitor 
panobinostat (PAN) in MM [257,134,136].  
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 
(PRC2), regulates the expression of thousands of genes to control developmental programs, 
maintain proliferative capacity and repress tumor suppressors in many forms of cancer 
[190,59,172,171,258–260]. EZH2’s canonical function is to repress gene expression via 
methylation of H3K27, however, EZH2 has recently been shown to have several additional 
catalytic and non-catalytic functions that regulate transcription factor complexes and non-coding 
RNAs [171,160,162–165].  
Following the initial observation that EZH2 is over expressed in aggressive myelomas [168,169], 
we demonstrated that EZH2 expression is driven by IL-6 and is required for the proliferation of 
growth-factor-independent human myeloma cell lines (HMCLs) harboring a ras mutation [170]. 
Since publishing these findings, corroborating evidence has accumulated suggesting that EZH2 is 
aberrantly active in MM and implicating EZH2 as a putative therapeutic target 
[186,147,185,183,182,179,184,180,152,261]. Characterization of recurring EZH2 activating 
mutations in lymphomas [174] has driven the recent development of several EZH2-specific 
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inhibitors (EZH2i’s: e.g. EPZ6438, GSK126 and UNC1999) which avoid the off-target effects of 
non-specific histone methyl-transferases inhibitors (i.e. DZNep) previously used to study EZH2 
[181,188,187,262,189,178].  
Recent efforts to evaluate the efficacy of EZH2 inhibitors in MM have further described a 
complex EZH2-mediated regulatory network that modulates the expression of many functionally 
significant miRNAs, MM-associated oncogenes and cell adhesion pathways [183,179,184,152]. 
Despite these findings, specific mechanisms of EZH2i-mediated cytotoxicity in HMCLs and 
biomarkers that distinguish EZH2i-sensitive myelomas remain elusive. Further, it is not clear that 
EZH2 inhibition is an effective treatment strategy in all myelomas. 
In the present study, we profile a large panel of HMCLs for EZH2i efficacy. We found that 
only a subset of HMCLs respond to single agent EZH2i, but all HMCLs respond to combination 
treatment with added HDAC inhibition. Additionally, comprehensive transcriptomic profiling of 
combination treatment reveals substantial changes in oncogenic pathways. 
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Materials and Methods: 
Drugs:  
Panobinostat/LBH-589(Novartis; Basel, Switzerland), GSK-126(GlaxoSmithKline; 
Brentford, U.K.) and Tazemetostat/EPZ-6438(Epizyme; Cambridge, MA) were purchased from 
Selleckchem (Panobinostat and EPZ-6438) and Cayman Chemical (GSK-126). All drugs were 
dissolved in DMSO (Sigma-Aldrich; St. Louis, MO) and stored at −20 °C. 
Cell culture and viability assays: 
Cell culture conditions for HMCLs used are previously described [263]. HMCLs were 
seeded at 4x105 cells per ml in 96-well plates and were treated with the primary drug (EZH2i) 
after 24hrs. Secondary treatment (panobinostat) was added at a small volume (32x) to minimize 
dilution of the primary treatment. Cell viability was measured using a CellTiter-Glo luminescent 
viability assay (Promega; Madison, WI) and a Synergy 2 Microplate Reader (BioTek; Winooski, 
VT). For propidium iodine exclusion assays, plated HMCLs were transferred to round bottom 96-
well plates (125μl/well), pelleted, resuspended in 200μl PBS containing 2μg propidium iodine, and 
propidium iodine staining was quantified using a BD FACSCantoII RUO Flow Cytometer (BD 
Biosciences; Franklin Lakes, NJ). Area under the survival curve (AUSC) was calculated using the 
trapezoidal method. Before AUSCs were compared to measure synergy each curve was 
individually normalized to the zero panobinostat condition. All viability data is normalized to 
untreated (i.e. media-treated) controls. 
Histone analysis 
Histones were isolated using a Histone Extraction Kit (Abcam; Cambridge, U.K.: 
ab113476). Extracted histone were western blotted for total H3 (CST; Danvers, MA: 96C10) and 
H3K27Me3 (CST: C36B11). Fluorescently labelled secondary antibodies (LICORE; Lincoln, NE: 
IRDye® 680RD and 800CW) were quantified with a LI-COR® fluorescence imager and 
densitometry was quantified in Image J (NIH). 
Transcriptomic profiling and analysis 
RNA was extracted (RNeasy Kit; QIAGEN) and stored in RNAlater™ (Invitrogen; 
Carlsbad, CA) at -80°C.  Biological triplicates were subjected to RNA-sequencing (RNA-seq) on a 
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HiSeq 2000 (Illumina; San Diego, CA) using 50bp single-end reads at a depth of >10 million 
reads per replicate. Sequencing data was processed and analyzed for differential expression 
using Galaxy [264] downstream analysis was conducted using the R programing language and 
Ingenuity Pathway Analysis (IPA; QIAGEN; Venlo, Netherlands). Differential expression was 
considered significant with an FDR<0.05 and FPKM values ≥ 1 for at least one value (control or 
treated).  
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Results: 
EZH2 inhibition reduces viability in a subset of human myeloma cell lines.   
To evaluate the single agent efficacy of EZH2 inhibition as an anti-MM therapeutic 
strategy we treated a panel of 14 human myeloma cell lines (HMCLs) with the selective EZH2 
inhibitors (EZH2i’s) EPZ-6438 and GSK-126. Treatment with these compounds for 4 days or less 
was insufficient to induce substantial reduction in viability measured via CellTiter-Glo®. After 9 
days of treatment, both compounds produced a consistent single agent response in a subset of 
cell lines (Figure 1a). These EZH2i sensitive cell lines demonstrated sensitivity at doses in the 
low micromolar range within a timeline consistent with others’ observations [187]. We also tested 
the EZH1/2 dual inhibitor UNC1999 in many of these HMCLs and observed very similar cytotoxic 
responses compared with EPZ-6438 and GSK-126 and no added sensitivity in EZH2i resistant 
cell lines upon dual inhibition (data not shown). 
To determine whether the lack of response in some HMCLs was due to a lack of target 
inhibition we extracted histones from treated cell lines to measure the relative abundance of 
global tri-methylated H3K27; a histone modification sufficient to measure global EZH2 catalytic 
activity [265]. Western blotting was performed on histones extracted from HMCLs treated with 
EZH2i’s for 6 days. Dual fluorescent labelling of total H3 and H3K27me3 (Figure 1b) allowed us 
to quantify (Figure 1c) the relative change in H3K27 de-methylation at different doses relative to 
an untreated control. Both EZH2i-resistant HMCLs (MMM1 and H929) and EZH2i–sensitive 
HMCLs (FLAM76 and SKMM2) showed a large decrease in the relative abundance of H3K27me3 
at doses well below 1μM, regardless of the effect on viability. Flam76 is a particularly sensitive 
cell line that is among the fastest to demonstrate viability loss after EZH2i treatment. This loss in 
viability explains the apparent decrease in detection of total H3 at higher EPZ-6438 doses. It is 
interesting to note that this loss of H3 detection occurs at higher doses (100-500nM) than doses 
required to reduce relative H3K27me3 (10-100nM). 
 
EZH2 inhibitor pre-treatment synergistically enhances sensitivity to the pan-HDAC 
inhibitor panobinostat.  
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Despite heterogeneous HMCL response to EZH2i’s, consistent changes in global H3K27 
methylation led us to consider that global epigenetic changes induced by EZH2i’s may sensitize 
HMCLs to other anti-MM compounds regardless of EZH2i single-agent response. To test this, we 
treated HMCLs with EZH2i’s in combination with several classes of compounds including 
proteasome inhibitors, immunomodulatory compounds and glucocorticoid receptor agonists, all of 
which failed to demonstrate consistent synergistic toxicity with EZH2i’s (data not shown). The 
pan-HDAC inhibitor panobinostat (Novartis), however, did consistently demonstrate a synergistic 
effect on HMCL viability. Initially, we found that simultaneously treating HMCLs with panobinostat 
and EZH2 inhibitors had little synergistic effect (Figure 2a). Pre-treating HMCLs with EZH2i’s for 
several days, however, strongly enhanced the cytotoxicity of panobinostat (Figure 2b). This was 
evident even in cases where the single agent EZH2i had no significant effect on viability. We 
further confirmed that relative loss in viability was cytotoxicity by measuring viability after 
combination treatment using CellTiter-Glo® in tandem with propidium iodine exclusion staining 
and flow cytometry (Figure S1).  
Many HMCLs lack a single agent response to EZH2i’s and therefore we were unable to 
quantitatively compare this synergistic interaction across a panel of HMCLs using the common 
Chou-Talalay method for generating combination index plots [266]. We chose instead to compare 
synergy by calculating the relative drop in the area under the survival curve (AUSC) between 
dose response curves of panobinostat alone and panobinostat combined with a fixed dose of 
EZH2i (each curve normalized to untreated or EZH2i-only controls) (Figure 2a,b). We 
systematically evaluated the normalized panobinostat AUSC decrease produced by pre-treatment 
with either EPZ-6438 or GSK-126 across a panel of 24 HMCLs (Figure 2c). We found that pre-
treatment with EZH2i’s strongly enhance the toxicity of panobinostat in almost all cases with 
consistent results between the two EZH2i’s. We additionally compared the effects of 
simultaneous EPZ-6438 treatment vs EPZ-6438 pre-treatment on panobinostat toxicity in the 
same HMCL panel (Figure S2). Pre-treatment with EZH2i’s was nearly always more effective. 
One drawback to the AUSC decrease metric is that in a few cases where the EZH2i single agent 
response is particularly strong, normalization can exaggerate the change in the shape of the 
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curve and therefore exaggerate the AUSC change or suggest antagonism (i.e. SKMM2 and 
FLAM76). Despite this, it was clear that pre-treatment with EZH2i’s had a strong dose-dependent 
effect (Figure 2d) on panobinostat efficacy regardless of EZH2i single agent toxicity across nearly 
all HMCLs tested.  
Having evaluated EZH2i sensitivity in several panel experiments we identified the 
following HMCLs as having demonstrated consistent EZH2i single agent sensitivity: SKMM2, 
FLAM76, KMS12BM, L363, MOLP8, MM1-144,  KAS61, MM1.S P and MM1.S VR. Overall our 
data did not suggest any trends between EZH2i sensitive and resistant HMCLs based on 
characterized genomic lesions including t(4;14), RAS mutation status and UTX/KDM6A mutation 
status (Table S1). 
 
EPZ-6438 induces robust transcriptomic change as a single agent and in combination with 
panobinostat.  
EZH2 and HDACs are both epigenetic regulators known to affect the expression of 
thousands of genes. We sought to determine if the enhanced cytotoxic response of the 
EZH2i/panobinostat combination is due to enhanced changes in the expression of a shared set of 
genes or if the combination produced a large set of gene expression changes that are unique to 
the combination. We selected 6 HMCLs to sample and screen for the ideal conditions to quantify 
transcriptomic changes via RNA-sequencing (RNA-seq): MMM1, SACHI, SKMM2, KMS20, 
KARPAS620 and FLAM76.  These HMCLs were selected to represent EZH2i-sensitivity (SKMM2 
& FLAM76) and EZH2i-resistance (MMM1, KARPAS620, KMS20 and SACHI). Samples were 
collected during days 0, 1, 2, 3, 4, 5.5 and 7 during treatment where EPZ-6438 (500nM or 5μM) 
or media was added at day 0 and panobinostat (two sub-IC50 concentrations per line 
experimentally determined during EZH2i pre-treatment) was added at day 4 as a single agent or 
as a combination with EPZ-6438 pre-treatment. We systematically evaluated these samples for 
viability and relative H3K27me3 levels (Figure S3) to identify the optimal doses and time points to 
submit paired samples for RNA-seq. Our results showed that demethylation of H3K27 was 
complete within the first three days regardless of EPZ-6438 dose. At that time SKMM2 and 
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FLAM76 also began to show a cytotoxic response to EPZ-6438. We chose to submit replicates 
for sequencing from MMM1 and FLAM76. We chose days 1, 4 and 5.5 that were treated with 
5μM for EPZ-6438 and 3nM/20nM panobinostat (FLAM76/MMM1 respectively).  
RNA-seq revealed large transcriptomic changes induced by EPZ-6438 (Figure 3a,b). Full 
differential expression data for each condition is provided as a supplemental file (File S1). 
Transcriptomic changes were minimal after one day of EZH2i treatment. This was expected given 
the time required for EZH2i-induced histone demethylation. 4 Days of treatment with EPZ-6438 
produced much more substantial gene expression changes with a clear bias towards global 
upregulation of gene expression in both HMCLs, which was expected following inhibition of a 
negative regulator of transcription. Gene expression changes that appeared on day 5.5 of 
treatment were roughly between two and three times the number of differentially expressed 
genes seen at Day 4. The magnitude of this continued change was surprising, as we did not 
expect additional deregulation to occur days after the global H3K27me3 levels had reached a 
minimum. To confirm the specificity of our sequencing between different time points we compared 
the number of genes conserved between different EPZ-6438 single agent treatment times and 
found that most of the genes identified in an earlier time point also appeared at the following time 
point (Figure 3b).  
Unfortunately, at the doses used, panobinostat only induced substantial gene expression 
changes in MMM1. While FLAM76 demonstrated little to no transcriptomic perturbation from 
panobinostat alone, the combination roughly doubled the number of differentially expressed 
genes measured from EPZ-6438 alone (758 to 1534 genes with at least a 2-fold expression 
change). MMM1 additionally demonstrated a very large increase in the number of genes effected 
by the combination over the two single agents. Comparing the overlap between the two single 
agent conditions with the combination it is clear that a large portion of differentially expressed 
genes identified in the combination are unique to the combination (Figure 3c).  In both cell lines, 
at a fold change threshold of ±2 roughly 2/3 of differentially expressed genes in the combination 
condition were unique to the combination. 
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We were surprised at the low degree of overlap (consistently below 20-25%) between the 
two cell lines at all conditions examined. The 758 (FLAM76) and 510 (MMM1) differentially 
expressed genes at day 5.5 of EPZ-6438 single agent treatment only had 92 overlapping genes.  
Additionally, there were only 183 genes shared between the 1891(FLAM76) and 1063(MMM1) 
genes unique to the combination. Another recent study using microarray transcriptomic analysis 
profiling different MM cell lines in response to EZH2 inhibition also noted little consistency in the 
magnitude and content of transcriptomic response [183]. It may be that the substantial epigenetic 
heterogeneity between patient tumors may not yield a predictable gene expression profile in 
response to EZH2 inhibition.  
 
Network analysis of EZH2i/HDACi transcriptomic profiles reveals highly enriched cancer-
related pathways and regulators.  
The magnitude of transcriptomic change in HMCLs treated with EPZ-6438, panobinostat 
and the combination required network analysis to identify higher order changes in established 
molecular pathways and functions. Ingenuity Pathway Analysis (IPA) [245] is a network analysis 
platform that can be queried with gene expression changes and return enriched network 
information from the QIAGEN knowledge base. Specifically, we considered significant enrichment 
of predicted upstream regulators (genes, groups or complexes), diseases/biological functions, 
and canonical pathways. We submitted filtered gene expression profiles (FDR<0.05 and |FC|>2) 
for all differential expression measurements and have included catalogs of all significant (p<0.05) 
hits returned (supplemental files S2-4). We compiled many of the top, contextually relevant hits 
into heat maps for each of the three analysis categories mentioned above (Figure 4a-c).  
It has been proposed that EZH2 promotes MM development by regulating the expression 
of numerous oncogenes and tumor suppressors [183,182,179,180]. Consistent with this, we 
observed that many of the upstream regulators predicted from our transcriptomic profiling are key 
in promoting MM development. For example, CCND1, a core regulator of cell cycle progression, 
has recurrent mutations in MM and is a highly enriched as a predicted upstream regulator in our 
transcriptomic profiles. MYC, an aberrantly expressed transcription factor in many cancers 
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including MM [267], is enriched in most of our transcriptomic profiles, has significantly lowered 
expression(Figure 4d) upon treatment with single agent EPZ-6438/combination in both HMCLs, 
and is strongly predicted to be deactivated upon combination treatment in both lines. Several 
additional hits have also been previously proposed to directly or indirectly interact with EZH2 
including NFKB [268], STAT1 [269], MYC [270,271], TP53 [258,268] and SMARCA4 [272]. IRF4, 
a late B-cell transcription factor, has recently been shown to facilitate EZH2i-sensitivity through 
BCL6-mediated downregulation in HMCLs harboring a UTX/KDM6A mutant background [152]. 
BCL6 is consistently enriched as a predicted upstream regulator in our data and IRF4 expression 
is downregulated upon combination treatment in both cell lines. It may be possible that the 
enhanced cytotoxicity of the combination treatment is due, at least in part, to synergistic 
regulation of key transcription factors such as IRF4 and MYC. Neither FLAM76 nor MMM1 have 
any known UTX/KDM6A mutations (J. Keats, personal communication) (Table S1).  
Several upstream regulator hits had a strong prediction of activation/deactivation. For 
example TP53, TNF, IFNA, IFNG, STAT1 and EIF2AK2 were all predicted as being strongly 
activated in most conditions suggesting a decreased oncogenic state and increased sensitivity to 
pro-apoptotic signaling. Examples of regulators with predicted deactivation included BTK, MAPK1 
and IRF4. BTK, a kinase critical for B-cell development, is a putative target in several cancers 
and BTK inhibitors have been shown to act synergistically with HDAC inhibitors in pre-clinical 
models of lymphoma [273]. While the modulation of these regulators may not be enough to drive 
cytotoxicity alone, they suggest a general reduction of the pro-growth/anti-apoptotic state of 
malignant plasma cells.  
The diseases and biological functions output from IPA highlighted gene ontology 
enrichment in many expected areas including hematologic cancers and cell death. Many key 
genes involved in cell death had some of the highest fold-change expression differences and 
suggested an increased pro-apoptotic state in single agent EPZ-6438 and to an even higher 
degree in the combination. These genes included the upregulation of PMAIP1 (NOXA), XAF1 and 
CDKN1A (p21) and the downregulation of BCL2 and XBP1(Figure 4d). Terms related to cell 
87 
 
adhesion and movement were highly represented. Modulation of cell adhesion has previously 
been shown to be a consequence of EZH2 inhibition in MM [183]. 
Canonical pathway analysis yielded many results that reflected some of the same genes 
enriched in upstream regulators. Some of the strongest and most consistent enrichments 
included the interferon signaling pathway and the antigen presentation pathway, both of which 
were  enriched after EPZ-6438 single agent treatment and the combination and have been shown 
to be directly modulated by EZH2 [269]. The interferon pathway has long been considered a 
target for therapeutic activation in MM [274]. Enrichment of this pathway was centered on the 
upregulation of STAT1 and most of its downstream promotor targets. The antigen presentation 
pathway showed a consistent increase in the upstream transcriptional coactivator CIITA and 
downstream MHC class II genes (Figure 4d). MHCII genes were among others enriched in the B-
cell development pathway where other B-cell markers were upregulated.  
While there were many consistent enrichments observed with EPZ-6438 single-agent 
treatment between lines there were few similarities when genes unique to the combination were 
submitted to IPA. A few exceptions to this include the predicted upregulation of the ‘sirtuin 
signaling pathway’ and enrichment of the ‘Endoplasmic Reticulum Stress Pathway’, 
‘Mitochondrial Dysfunction’ and ‘tRNA Charging’ pathways. Another consistency between both 
unique-to-combination genes was the strong predicted activation of cell death and apoptosis 
related ontology terms. 
In general, network analysis of EZH2i-induced gene expression changes revealed a 
consistent modulation of cancer-related pathways in a manner suggesting a less growth-
promoting state. The combination with panobinostat indicated strong predictions of cell-
stress/death in addition to further perturbation of the pathways identified in the single agents. 
While many of these factors were previously known to be downstream of EZH2 inhibition, the 
combination with panobinostat illuminated an enhanced augmentation of tumor-promoting 
pathways as well as several enriched results unique to the combination.   
88 
 
Discussion: 
Recent development of EZH2-specific inhibitors has prompted several studies evaluating 
the efficacy of EZH2 inhibition in HMCLs. Several of these studies have identified significant 
pathways and regulators that are modulated in HMCLs upon EZH2 inhibition including 
contextually relevant oncogenes/tumor suppressors  [183,179,184,152], novel miRNAs [179], 
cell-to-cell adhesion/mobility [183] and dysregulation of cell cycle control [180]. Our evaluation of 
a large panel of HMCLs for single agent cytotoxic response to EPZ-6438 and GSK-126 
recapitulated previously described dose and temporal thresholds for cytotoxicity in HMCLs. Other 
studies that have evaluated EZH2i’s in HMCLs have measured baseline EZH2 protein levels and 
did not demonstrate a correlation with single agent sensitivity [183,180]. Some recent studies 
have proposed that certain subsets of MM are sensitive to EZH2 inhibition such as MM cases 
harboring recurring UTX/KDM6A loss-of-function mutations or recurring t(4:14) translocation, both 
of which are known to directly impact modification EZH2’s target residue and alter EZH2 
distribution respectively [152]. The relative sensitivity and resistance for HMCLs that were shared 
between our evaluation and that of others was generally consistent. In HMCLs not examined by 
others, predictions of sensitivity based on subtype were consistent in some cases (sensitivity in 
UTX mutant KMS12, L363 and t(4:14) containing KAS61) and inconsistent in others (resistance in 
t(4:14) containing OPM2, PE2, H929, JIM3 as well as UTMC2 that contains both t(4:14) and UTX 
lesions) (Table S1). As speculated by others [152], these specific lesion may be sufficient to 
distinguish sensitivity in certain genomic/epigenomic contexts, however other factors clearly play 
a role in effecting single agent sensitivity.  
To our knowledge, we are the first to report enhancement of HMCL sensitivity to 
panobinostat via EZH2i pre-treatment. Panobinostat has recently been approved for use in 
refractory MM, however its therapeutic benefit has been modest [134]. Therefore, combination 
therapies that enhance HDACi efficacy could have great therapeutic benefit. We found that this 
synergistic interaction did not require EZH2i single agent sensitivity. This synergistic interaction 
has been explored in other cancer contexts [275–277] however the combination has yet to be 
applied in any clinical trials. Encouragingly, one study found that combining panobinostat with a 
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non-specific inhibitor of methyltransferase activity (DZNep) was tolerated in a murine xenograft 
model of AML [278] suggesting that EZH2i/panobinostat combination may not produce undue in 
vivo toxicity.  
We were surprised by how many EPZ-6438-induced transcriptomic changes were observed well 
after global H3K27 levels had reached a minimum. Extensive global/temporal profiling of 
chromatin will be required to determine if these final expression changes are direct effects of 
EZH2i or if they are rather pleiotropic fallout from the substantial epigenetic modification. We 
have postulated that upregulating the expression of so many genes may result in some non-
specific toxicity. This could, in part, explain consistent toxicity of the combination treatment 
despite an apparent lack of overlap between differentially expressed genes. With a more lenient 
1.5 fold-change threshold, combination treatment in FLAM76 and MMM1 showed as much as a 
roughly 15% and 22% significant differential expression of the queried genome. While the 
contribution of non-specific transcriptomic stress remains speculative, it is clear is that the 
combination of the two inhibitors upregulated a large set of genes that were unique to the 
combination. This suggests that PRC2 and HDACs likely cooperate to silence a large portion of 
the genome and that this cooperation may be essential for the survival of myelomas that exploit 
aberrant PRC2 activity.  
Our network analysis largely corroborated findings that EZH2 inhibition leads to a robust 
upregulation of tumor suppressors and concomitant downregulation of oncogenic pathways. 
These pathways included key regulators of cell-to-cell interaction, antigen presentation, 
differentiation, apoptosis, cell cycle progression, metabolism and central signaling nodes such as 
MYC and TP53. MYC, a classic anti-cancer target for which there is no selective small compound 
inhibitor, seems to be particularly implicated in recent literature describing the anti-cancer effects 
of EZH2 inhibition  [258,179,152,270,271]. It remains unclear if these factors and pathways 
directly induce cytotoxicity in combination treatment or if the combined transcriptomic change 
pushes HMCLs towards a more apoptosis-permissive state that is perturbed by the direct toxicity 
of panobinostat.  
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The magnitude of transcriptomic change and network analysis hits, both shared and 
distinct between the two lines, in addition to the low degree of overlap between the two lines 
presents a challenge in discerning definitive biomarkers for EZH2i sensitivity. Any attempt to 
define a consistent consensus EZH2i gene expression profile in HMCLs or to identify biomarkers 
for sensitivity would require a much more exhaustive transcriptomic profiling of a large panel of 
HMCLs. Even in that case, we speculate, as others have [183], that identifying a predictive 
signature or single sensitivity biomarker for a highly networked regulator targeting thousands of 
genes in an extremely epigenetically heterogeneous disease background is a dubious prospect. 
Despite these challenges towards defining the scope of PRC2/HDAC interaction specific to MM, 
accumulating evidence suggests a generalized effect including downregulation of oncogenic 
pathways and upregulation of tumor suppressors. This leads to either direct cytotoxicity or 
sensitization of HMCLs to combination therapies in a targeted manner. 
In conclusion, our data suggests that while only a subset of human myeloma cell lines 
respond to EZH2 inhibition, nearly all lines tested were effectively targeted for cell death through 
a synergistic combination of panobinostat and EZH2 inhibitor pre-treatment. This combination 
was effective at lowering the therapeutic threshold of panobinostat even in cases where there 
was no single agent EZH2 inhibitor response. Transcriptomic analysis of single agents and 
combination treatments corroborates the regulation of many oncogenic pathways towards a less 
growth-promoting state and reveals a large transcriptomic response unique to the drug 
combination. These data support the further evaluation of therapeutic combination to broadly 
target aggressive MM in in vivo and clinical contexts.  
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Supplemental figures and tables appear below. Supplementary data files are included 
with the submission of this thesis: 
Supplemental file descriptions: 
• File S1(.xlsx): Full differential expression results from RNA-seq experiments in both cell lines. 
Each differential expression condition (treatment vs untreated control) is on its own tab. In 
each tab genes with no detectable expression in either control or treatment have been 
removed. Infinite (positive or negative) ‘log2.fold.change’ values are represented by ‘#NUM!’ 
in .xlsx format.  
• File S2(.xlsx): Full catalog of Ingenuity Pathway Analysis (QIAGEN) results: canonical 
pathway analysis. Each differential expression condition (treatment vs untreated control) is on 
its own tab. Activation z-scores absent when not provided by IPA.  
• File S3(.xlsx): Full catalog of Ingenuity Pathway Analysis (QIAGEN) results: upstream 
regulator analysis. Each differential expression condition (treatment vs untreated control) is 
on its own tab. Activation z -scores absent when not provided by IPA. 
• File S4(.xlsx): Full catalog of Ingenuity Pathway Analysis (QIAGEN) results: disease and 
biological functions analysis. Each differential expression condition (treatment vs untreated 
control) is on its own tab. Activation z -scores absent when not provided by IPA.  
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Figure legends: 
Figure 1: EZH2 inhibition induces H3K27 demethylation in all HMCLs and decreases viability in a 
subset of HMCLs.  
(a) A panel of 14 HMCLs were treated with a concentration range of EZH2 inhibitors EPZ-6438 
and GSK-126 for either 4 or 9 days. Viability was measured with CellTiter-Glo® (Promega) 
assays and normalized to untreated controls. (b) H3K27 demethylation was quantified after a 6 
day treatment with a range of EZH2 inhibitors in two EZH2i-sensitive (FLAM76 and SKMM2) and 
two EZH2i-resistant (MMM1 and H929) HMCLs. H3K27me3 was quantified by western blot where 
total histone 3 (mouse anti-H3; CST#3638) and H3K27me3 (rabbit anti-H3K27me3; CST#9733) 
were simultaneously quantified via a LI-COR® fluorescence reader. Relative densitometry (c) 
was calculated for each EZH2i concentration and normalized to the untreated control. All error 
bars represent SEM between biological replicates. 
Figure 2: EZH2 inhibitor pre-treatment sensitizes HMCLs to panobinostat in a dose-dependent 
manner.  
HMCLs were treated with a combination of the pan-HDAC inhibitor panobinostat and EZH2 
inhibitors GSK-126 or EPZ-6438. Viability was measured via CellTiter-Glo® and normalized to 
untreated controls. Two treatment schedules (represented by schematics in (a) and (b)) were 
applied and data is represented in the HMCL UTMC2 where EPZ-6438 was either combined with 
panobinostat simultaneously (a) or 5 days prior to panobinostat (b). Bar plots represent a 
measurement of synergy quantified by the decrease in the area under the survival curve (AUSC) 
between panobinostat single agent treatment and combination treatment (where AUSC of each 
EZH2i+pan/CTRL+pan dose response curve is normalized separately to isolate the shape of the 
curve from single agent EZH2i toxicity). (c) A panel of HMCLs (n = 24) were treated with 
panobinostat for 48hrs after a 4-day pre-treatment with either GSK-126 or EPZ-6438. The 
resulting synergy is represented as decrease in normalized AUSC across the HMCL panel. (d) 
Three HMCLs representing three levels of EZH2i sensitivity (none, minimal and strong) were pre-
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treated with a range of EPZ-6438 concentrations for 7 days followed by treatment with a constant 
range of panobinostat for 48hrs. Viability was measured via CellTiter-Glo®. All error bars 
represent SEM between biological replicates. 
 
Figure 3: Transcriptomic profiling of EPZ-6438/Panobinostat single agents and combination.  
(a) All significant (FDR<0.05, FPKM≥1) gene expression changes for two HMCLs (FLAM76 & 
MMM1) treated with EPZ-6438 (5μM for 1,4 or 5.5 days) and/or panobinostat (FLAM76-
3nM;MMM1-20nM for 1.5 days after 4 days EPZ-6438/media pre-treatment). Infinite/negative-
infinite fold change values (i.e. 0 FPKM relative to 10 FPKM) display the same color saturation as 
the finite minimum or maximum fold change value. (b) Pie charts each representing the total 
number (center) of upregulated (red) and downregulated (green) genes (FDR<0.05, FPKM≥1) for 
each treatment condition. At each condition two fold change thresholds are displayed (|FC|≥2 
above and |FC|≥2 below) for both HMCLs as well as for the overlap in significant gene expression 
changes for each condition/threshold between the two HMCLs. Arrowed lines between sampling 
days display the number of upregulated (red arrow) and downregulated (green arrow) genes 
shared between the three different EPZ-6438 single agent sampling times. (c) Venn Diagrams 
displaying genes shared between the day 5.5 EPZ-6438, panobinostat and combo differential 
expression conditions as well as the genes unique to the combination. The dotted arrow/number 
represent genes unique to the combination that are shared between the two HMCLs.  
Figure 4: Ingenuity Pathway Analysis of EPZ-6438-, panobinostat-, and combination-induced 
gene expression changes.  
Filtered differential gene expression profiles (FPKM≥1, |FC|≥2,FDR<0.05) for two HMCLs 
(FLAM76 & MMM1) treated with EPZ-6438(μM), panobinostat(FLAM76-3nM;MMM1-20nM) or the 
combination (relative to time-matched untreated control) were subjected to Ingenuity Pathway 
Analysis (IPA). Heat maps represent selected top results from different types of IPA analysis: (a) 
predicted upstream regulators (genes, groups or complexes), (b) enriched disease and biological 
functions and (c) enriched canonical pathways. Each differential expression condition is 
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represented by two columns. The left column displays the –log10(p-value) returned by IPA for 
enrichment and the right column displays the predicted activation z-score (when applicable; not 
all predictions have activation directionality). Analysis of unique-to-combination (UTC) genes 
subsetted from the combination condition for each line is also displayed. White heat map cells 
represent a lack of significant enrichment/prediction (p>0.05 and |z|<2 respectively). Grey heat 
map cells represent missing activation z-scores when p-values are significant.  (d) differential 
expression (RNA-seq: log2 fold change) across all conditions for selected genes pertinent to top 
IPA hits and discussed in text. Only gene expression changes significant at FDR<0.05 and 
|fc|>1.5 are displayed.  
Figure S1: Cytotoxicity of EZH2i and Panobinostat combination is confirmed via propidium iodine 
exclusion assay.  
Four HMCLs seeded in 96-well plates were treated for 48hrs with either panobinostat or the 
protesome inhibitor bortezomib (Takeda). These treatments were preceded by a 5-day treatment 
with either 5μM EPZ-6438 (panobinostat only) or media. After the 48hr secondary treatment 
plates were sampled and assayed for viability by both CellTiter-Glo® (a) and propidium iodine 
(PI) staining followed by flow cytometry (b) in tandem. All error bars represent SEM between 
biological replicates. 
Figure S2: EPZ-6438 sensitizing of HMCLs to panobinostat is consistently more effective as a 
pre-treatment across an HMCL panel.  
24 HMCLs were either pre-treated with EPZ-6438 for 5 days followed by a 48hr panobinostat 
treatment (“pre-treated”) or they were pre-treated with media for 5 days followed by a 48hr 
simultaneous treatment with EPZ-6438 and panobinostat. In both cases two doses of EPZ-6438 
were evaluated (0.5μM & 5μM). Viability was measured via CellTiter-Glo® and synergy is 
represented by the decrease in normalized AUSC between single agent panobinostat and the 
combination treatment. Negative values represent an increase in normalized AUSC. 
Figure S3: Time-course measurement of H3K37 demethylation and cell viability after treatment 
with EPZ-6438, panobinostat and the combination in 6 HMCLs.  
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6 HMCLs (MMM1, SACHI, SKMM2, KMS20, KARPAS620 and FLAM76) were sampled at 0, 1, 2, 
3, 4, 5.5 and 7 days post-treatment with 500nM EPZ-6438, 5μM EPZ-6438 or media (untreated 
control). Cells additionally treated with panobinostat (single agent and combined with EPZ-6438 4 day 
pre-treatment) on day 4 in this sampling schedule were harvested on days 5.5 and 7. Samples were either 
(a) immediately measured for viability via CellTiter-Glo® (normalized to time-matched untreated 
control) or subjected to histone-purification and storage at -80⁰C. Frozen histone preparations 
were later western blotted and quantified (b) for H3K27me3 abundance (each sampling day 
normalized to total H3). 
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Table S1: List of human myeloma cell lines used in this study with annotated UTX/KDM6A, RAS 
and t(4;14) status  
‘ND’ = no data. ‘WT’ = wild type. Zygosity is not specified in every case. HMCL status data is 
sourced from the Keat’s lab repository (http://www.keatslab.org/data-repository) and recently 
published data [152]. HMCLs demonstrating consistent sensitivity to EZH2 inhibition in our 
experiments appear below in red.  
MM cell line UTX/KDM6A status RAS status t(4;14) 
ARD Homozygous mutation ND No 
ARP1-1C WT WT No 
DELTA97 WT WT No 
FLAM76 WT WT No 
H929 WT NRAS mutation Yes 
JIM3 WT KRAS mutation Yes 
KARPAS620 WT KRAS mutation No 
KAS61 WT WT Yes 
KMS12BM mutation WT No 
KMS20 WT KRAS mutation No 
KMS28PE Homozygous mutation KRAS heterozygous mutation Yes 
L363 mutation NRAS mutation No 
MM1.S WT KRAS mutation No 
MM1.S VR WT KRAS mutation No 
MM1-144 ND ND ND 
MMM1 WT NRAS mutation No 
MOLP8 WT NRAS mutation No 
OCIMY1 WT KRAS mutation No 
OPM2 WT FGFR3 mutation Yes 
PE2 WT NRAS mutation Yes 
SACHI WT WT No 
SKMM1 WT NRAS mutation No 
SKMM2 WT WT No 
U266 WT BRAF mutation No 
U266 VR WT BRAF mutation No 
UTMC2 Homozygous mutation WT Yes 
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FIGURE 4 continued 
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CHAPTER 4  
SUPPLEMENTAL CHAPTER: UNPUBLISHED FINDINGS RELATING TO COMBINED 
TREATMENT OF EZH2 AND HDAC INHIBITORS IN HUMAN MYELOMA CELL LINES 
This supplementary chapter expands on the study outlined in Chapter 3. Specifically, this 
chapter contains additional data that was either alluded to in the previous chapter or was not 
included in submissions for publication.  
Chapter 3 outlined evaluation of efficacy of two EZH2 inhibitors against a panel of 
HMCLs: EPZ-6438 and GSK-126. These two inhibitors specifically target EZH2. Some interest 
has also been generated around dual inhibitors that target EZH2 and EZH1, a related HMT that 
can replace EZH2 as the core catalytic subunit of the polycomb repressive complex 2 (PRC2). 
Little to nothing is described in the literature regarding EZH1’s activity or expression in MM, 
however, some studies in other cancers and MM suggest an added benefit of using EZH1/2 dual 
inhibitors [279,280].  
To test the efficacy of dual inhibition in tandem with EZH2i, we treated 12 HMCLs with all 
three inhibitors: EZH2-specific inhibitors EPZ-6438, GSK-126 and dual inhibitor UNC1999 [189] 
(Figure 1). All three drugs were applied with the same concentration gradient and viability was 
read after 4,6,10 and 18 days post treatment. UNC1999 did demonstrate 100% kill at 30μM in all 
HMCLs and time points, however this is similar to high-dose toxicity observed in GSK-126 (data 
not shown). In both of those instances this high does toxicity was markedly more rapid than the 
timeline required for lower dose response and latent sensitivity in some lines was achieved at 
much lower (up to an entire order of magnitude) doses. Together this suggests an off-target effect 
of extreme doses.  
There was no general trend towards selective sensitivity to the dual inhibitor. In many 
instances UNC1999 kill curves mirrored EPZ-6438, however there were instances of lower dose 
sensitivity in MOLP8. It would be interesting to follow up this finding by measuring EZH1 
expression levels in MOLP8 compared to other HMCLs.  
In Chapter 3 synergy between EZH2i’s and panobinostat was assessed by comparing 
changes in the area under the survival curve (AUSC). This metric was useful for condensing the 
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data into a manuscript. The individual kill curves used to generate Figure 2c in Chapter 3 are 
included as Figure 2 in this chapter.  
Panobinostat is a pan-HDAC inhibitor. We sought to determine if certain broad classes of 
HDADs are specifically responsible for the synergy observed between EZH2i’s and panobinostat. 
As overviewed in the introduction, HDACs are a large family of enzymes that are segregated into 
classes based on homology to yeast HDACs. HDAC6, a class IIb HDAC is exclusively 
cytoplasmic and, as discussed in Chapter 1, is of particular interest in MM. We sought to 
determine if Inhibition of HDAC6 via tubacin and nexturastat A would recapitulate panobinostat’s 
synergy with EZH2i-pre-treatment in four HMCLs that had demonstrated consistent and strong 
synergy. Conversely, we also applied inhibitors that target all other HDACs (classes I,IIa and IV): 
sodium butyrate and valproic acid (Figure 3). Interestingly, synergy was observed to nearly 
recapitulate AUSC changes seen with panobinostat, with the exception of tubacin which did 
demonstrated relatively mild synergy. These data suggest that EZH2i pre-treatment may be 
sufficient to potentiate sensitivity to both broad types of HDACs. This suggests that either synergy 
seen in panobinostat is due to several different synergistic mechanisms or that this synergistic 
toxicity may be non-specific.  
We were intrigued by the large number of unique-to-combination (UTC) genes identified 
in our transcriptomic analysis of HMCLs treated with both EPZ-6438 and panobinostat. This 
clearly suggested to us that EZH2 cooperates with HDACs to silence thousands of genes that 
cannot be freed from repression by inhibition of either alone. We were further surprised that UTC 
genes, when subjected to network analysis via IPA, did not demonstrate additional enrichment of 
terms (vs. EZH2i or panobinostat alone) commensurate with the nearly two thirds of genes 
identified at the combination that were UTC. This led us to postulate that these genes may not 
represent a controlled epigenetic network as is suggested for EZH2i-induced GEPs (presumably 
cells never abolish activities of all HDACs in any viable context). Rather, these genes are non-
specifically overexpressed, which we have postulated could, at that magnitude, produce non-
specific transcriptomic stress where transcription machinery is overloaded. When we looked at 
the most highly expressed genes that were significantly differentially expressed in the 
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combination condition in both HMCLs there seemed to be a strong bias towards downregulation. 
To examine this trend globally we visualized our drug induced (individual and combination) GEPs 
in a plot similar to a volcano plot except that the x-axis represents ranked expression of genes 
(filtered for significant differential expression) in the control condition (untreated) and the y-axis 
represents the change in expression for each gene (log2(1+FPKM_change)). This allows one to 
view trends in gene expression changes with even density across the data (Figure 4). While less 
consistent/clear in earlier time points or single agents, the bias towards downregulation of highly 
expressed genes was clearer in combination conditions in both HMCLs. It is important to note 
that these differences could represent compression of the transcriptomic data. That is to say that 
upregulation of so many low expressed genes may cause the highly expressed genes to become 
less frequently represented in raw reads. Indeed, if this were to be the case, one would expect 
that the mean FPKM change per gene would be close to 0 as it is in FLAM76 (mean 
FPKM_change/gene = 3.69). In MMM1 however this mean change per gene is -17.27 showing a 
clearer bias towards downregulation. This is far from a conclusive evidence of transcriptomic 
stress as a mechanism for cytotoxicity. It would be interesting to test if titrating down 
transcriptomic capacity with transcription inhibitors would demonstrate significant synergy with 
either EZH2 inhibitors or HDAC inhibitors.   
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Figure Legends 
Figure 1: EZH2 inhibition yields similar efficacy to dual inhibition of EZH2 and EZH1. 
A panel of 12 HMCLs were treated with a concentration gradient of two EZH2 inhibitors EPZ-
6438 and GSK-126 and one EZH2/1 dual inhibitor UNC1999. Viability was measured 
(resampling) after treatment for 4, 6, 10 and 12 days. Viability was measured with CellTiter-Glo® 
(Promega) assays and normalized to untreated controls. All error bars represent SEM between 
biological replicates. 
 
Figure 2: Combination of EZH2 inhibition and panobinostat across a panel of 24 HMCLs 
A panel of HMCLs (n = 24) were treated with panobinostat for 48hrs after a 4-day pre-treatment 
with either GSK-126 or EPZ-6438. Viability was measured with CellTiter-Glo® (Promega) assays 
and normalized to untreated controls. All error bars represent SEM between biological replicates. 
 
Figure 3: HDAC inhibitors either targeting class IIb HDACs or all other HDACs both demonstrate 
synergy with EZH2i pre-treatment. 
Each HMCL (arranged vertically) is represented by two plots both showing HMCLs treated with 
three drugs (control (solid) and EPZ-6438 pre-treated (dotted)), one of which is panobinostat. 
Plots on the left show treatment with HDAC6-specific inhibitors nexturastat A and tubacin. Plots 
on the right show treatment with sodium butyrate and valproic acid. Viability was measured via 
CellTiter-Glo® and normalized to untreated controls. Bar plots represent a measurement of 
synergy quantified by the decrease in the area under the survival curve (AUSC) between 
panobinostat single agent treatment and combination treatment (where AUSC of each 
EZH2i+pan/CTRL+pan dose response curve is normalized separately to isolate the shape of the 
curve from single agent EZH2i toxicity). All error bars represent SEM between biological 
replicates. 
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Figure 4: Transcriptomic analysis suggests potential biases in the direction of gene expression 
changes.  
Each scatter plot (generated using the ggplot2 R package) represents all of the differentially 
expreassed genes for a particular differential expression experiment in either MMM1 (a-e) and 
FLAM76 (f-j). The x-axis in these plots is rank order for expression (FPKM) values in the 
untreated condition while the y-axis represents the change in expression observed in the 
differential expression measurement (log2(1+FPKM_change). The trend-line indicates a 
smoothed mean expression change along the x-axis. The text appearing in the bottom left 
displays calculated average FPKM changes for all, upregulated and downregulated genes. Blue 
lines indicate control FPKM values  at increasing orders of magnitude (starting at FPKM = 10 on 
the left).   
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FIGURE 1 continued 
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FIGURE 1 continued 
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FIGURE 2 continued 
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FIGURE 2 continued 
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FIGURE 3 
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Figure 4a (MMM1 - Day 1 - EPZ-6438) 
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Figure 4b (MMM1 - Day 4 - EPZ-6438) 
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Figure 4c (MMM1 - Day 5.5 - Panobinostat) 
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Figure 4d (MMM1 - Day 5.5 - EPZ-6438) 
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Figure 4e (MMM1 - Day 5.5 – EPZ-6438 + Panobinostat) 
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Figure 4f (FLAM76 - Day 1 - EPZ-6438) 
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Figure 4g (FLAM76 - Day 4 - EPZ-6438) 
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Figure 4h (FLAM76 - Day 5.5 - panobinostat) 
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Figure 4i (FLAM76 - Day 5.5 - EPZ-6438) 
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Figure 4j (FLAM76 - Day 5.5 - EPZ-6438 + panobinostat) 
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CHAPTER 5 
DISCUSSION AND FUTURE AIMS 
The next decade will be an incredibly exciting time to be involved in cancer research. New 
quantitative ‘omics’ technologies developed in the post-genomic era have vastly expanded our 
understanding of the biological mechanisms malignant cells use to initiate/sustain erroneous 
proliferation and evade standard-of-care therapies. The future of oncology will likely see a 
marriage of these profiling technologies with disease management; a union that will set the stage 
for precision medicine that utilizes the great body of accumulated knowledge to direct therapy 
towards the most fruitful outcome [214]. While personalized medicine seeks to categorize 
patients, other technologies, founded on our increasing understanding of immune biology, have 
immense promise to broadly target certain malignant cell types via the host immune system [197]. 
Other broad targeting therapies have begun to emerge from our relatively newfound appreciation 
for cancer epigenetics. While cancer biology has traditionally been a field that has studies the 
impact of specific oncogenic/tumor suppressor pathways, interest has surged towards 
understanding how cancer cells exploit epigenetic regulation of broad cellular processes to 
govern proliferation and microenvironment interactions [256]. Studies born out of this surge in 
interest have fomented the development a number of small compound inhibitors that have the 
potential to exploit cancer epigenomes with broad applicability. While these examples serve to 
elevate hope in the future of cancer biology, many cantankerous obstacles still block the road to a 
cure.  
The introduction to this dissertation described MM as an immensely complex and highly 
heterogeneous disease. A diverse set of germinal-center-based genomic lesions initiate pre-
malignancy. After terminal differentiation to the plasma cell stage, accumulate additional CNVs, 
translocations, somatic mutations and a reprogrammed epigenome until the malignant plasma 
cell burden in the bone marrow microenvironment ultimately prompts the diagnosis of MM [48]. 
These numerous roads, all leading to the singular diagnosis, exemplify the widespread 
heterogeneity present between MM patients. It should be no surprise that oncologists struggle to 
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manage this pernicious and often refractory malignancy with a limited palette of therapeutic 
options [191].  
Addition of certain therapies to standard anti-MM therapeutic regimens (i.e. proteasome 
inhibitors and immunomodulatory drugs) have positively impacted disease management, however 
MM remains incurable due to inevitable drug-resistant relapse. In light of this, there is a profound 
need to expand the number of therapeutic options that are available to clinicians. These include 
therapies that both target specific sub-sets of the patient population and more broadly target MM 
despite genomic heterogeneity. Furthermore, such diverse options in treatment must absolutely 
be accompanied by profiling strategies that direct therapy to the most efficacious option prior to 
administration of ineffective and resistance-cultivating therapies.   
 The second chapter of this dissertation outlines a study that identified a 42-gene gene 
expression profile (GEP) that distinguishes extreme sensitivity/resistance to proteasome inhibitors 
(PIs). Proteasome inhibitors have been widely applied in MM therapy for over a decade. During 
this time, the problem of refraction/resistance to PIs has increasingly precipitated studies that 
have attempted to identify specific biomarkers for sensitivity/resistance. Dutifully following the 
literature on this subject in recent years have revealed a myriad of factors that seem to contribute 
to proteasome inhibitor resistance. While some biologically significant information can be gleaned 
from many of these studies, many of them suffer from the same pitfall: a lack of broad 
examination across a large number of cell lines [222]. Many studies attempting to distinguish 
sensitivity and resistance in MM (to PIs and other anti-MM therapies) perform experiments in only 
a handful of HMCLs, failing to address the broad context of disease heterogeneity.  
In this study [217], we executed an unprecedented effort to systematically profile 
chemosensitivity to four proteasome inhibitors across a large (50+) panel of HMCLs. We 
observed that our HMCL panel displayed a broad distribution of cytotoxic response to therapy, 
not unlike the distribution of response present in the MM patient population. We importantly 
confirmed that all four PIs generally share significant overlap in response distribution. There were, 
however, some exceptions to this trend, suggesting that in some instances, certain HMCLs have 
adopted resistance mechanisms that are selective among proteasome inhibitors despite a 
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seemingly similar mechanism of action. This implies that, in some cases of refraction/relapse, 
other proteasome inhibitors may remain as therapeutic options. Attempting to elucidate the 
specific mechanisms that underpin selective resistance among proteasome inhibitors may shed 
light on interesting pharmacodynamic differences between these inhibitors.  
 Transcriptomic differences between HMCLs in the top and bottom deciles of the chemo 
sensitivity distribution revealed a large set of common distinguishing genes. Stringent 
thresholding to select only the most consistent genes yielded a 42-gene signature. Unsurprisingly 
several genes identified in this signature are directly or indirectly related to the ubiquitin 
proteasome system and endoplasmic reticulum stress.  
 Using this 42-gene signature our then post-doctoral researcher Amit Mitra, Ph.D. used 
publically available data to cluster patient data and train supervised ensemble machine learning 
algorithms (random forest and random survival forest). These efforts demonstrated that although 
our GEP was generated on only a handful of cell lines, these genes can successfully stratify 
patient populations under PI-including therapeutic regimens between good and poor responders. 
Importantly this was only true in clinical trial arms that contained PIs, suggesting that this 
signature is indeed drug specific. 
 Until recently, the notion of empirically testing GEPs to determine if these expression 
changes, as a group, are sufficient to drive resistance or therapy was not feasible. The advent of 
CRISPR-Cas9 genome engineering has raised a number of new possibilities. Specifically, it may 
be possible to multiplex guide RNAs that direct catalytically null Cas9 nucleases conjugated to 
enhancers or repressors of transcription (CRISPRa/CRISPRi) to precisely modulate the 
expression of several genes in tandem [281]. Several technical aspects are obstacles to such an 
approach. Despite this, it may soon be feasible to test drug-sensitivity GEPs directly in HMCLs to 
better understand the degree to which these transcriptomic changes are functionally causative.  
 Our laboratory has begun testing the ability of GEPs to distinguish sensitivity and 
resistance of sub-clones present in MM samples and cell lines. Single cell sequencing 
technologies are still in their infancy, yet they have immense promise to identify drug resistant 
sub-clones within a tumor that may flag a patient as harboring innate resistance to therapy. Our 
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recent publication [234] provides a bioinformatics pipeline for processing single cell sequencing 
(targeted) data and identifying drug resistant clones based on a predictive-GEP. This proof-of-
principle study suggests that such an approach may have clinical utility. Both this and the 
experimental methods outlined in the preceding paragraph have just been funded for further 
evaluation/development and will be a continued area of research in the Van Ness laboratory. 
 The 3rd and 4th chapters of this dissertation articulate a study that tests methods to target 
the myeloma epigenome. Therapeutic strategies that target the epigenome have gained great 
momentum in recent years as epigenetic abnormalities are increasingly recognized as a core 
aspect of cancer development. MM is no exception to this.  
The epigenetic repressor of transcription EZH2 initially became a gene of interest for the 
Van Ness laboratory in 2005 when a former graduate student, Paula Croonquist, described EZH2 
as an oncogene in MM and demonstrated that EZH2 knockdown is sufficient to arrest MM growth 
[170]. At the time, a lack of small compounds that specifically inhibit EZH2 temporarily stifled our 
labs interest in EZH2 as we have always been interested in evaluating pre-clinical models that 
have potential translational impact in therapeutic contexts. Since Paula’s 2005 Oncogene paper, 
a compendium of evidence has accumulated implicating EZH2 as a driver of many forms of 
cancer, namely lymphomas with gain-of-function mutations. Development of compounds that 
inhibit EZH2, along with new evidence corroborating EZH2 as being aberrantly active in MM, 
reignited our interest in evaluating EZH2 as a target for therapy in MM.  
My study on this subject demonstrated that two EZH2 inhibitors (EZH2i’s: EPZ-6438 and 
GSK-126) do have single agent efficacy in less than half of the HMCLs tested. This initial finding 
has since been corroborated by other recent publications examining the efficacy of these EZH2i’s 
in MM. We were initially surprised to find that even in cases of resistance, H3K27 was robustly 
demethylated. This suggested that EZH2 inhibition in HMCLs did induce presumably massive 
remodeling of the MM epigenetic landscape in all cases, yet this change was only sometimes 
cytotoxic. This led us to postulate that EZH2i remodeling of the epigenome may potentiate 
response to current anti-MM therapies. Indeed we found that EZH2i pre-treatment strongly 
potentiate sensitivity towards the pan-HDAC inhibitor panobinostat in nearly all cases. Excitingly, 
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this this drug combination was effective even in HMCLs that had previously demonstrated the 
most extreme resistance to PIs.  
While this drug combination is particularly relevant to MM due to the recent FDA approval 
of panobinostat for relapsed/refractory MM [135,136], it remains possible that other compounds 
may also be potentiated by EZH2i pre-treatment. EZH2’s aberrant activity in MM (contrasting its 
lack of expression in healthy plasma cells) presents a specific target for EZH2i’s. It would be 
informative to screen HMCLs pre-treated with EZH2i’s for induced sensitivity to various anti-
cancer compounds. Such a high throughput approach could illuminate new strategies to 
specifically target malignant plasma cells while also further elucidating the biological scope of 
EZH2 activity in MM cells.  
Transcriptomic analysis revealed that combining of EZH2 inhibition with panobinostat in 
HMCLs modulates the expression of thousands of genes. This was no surprise as the targets of 
both drugs are individually known to regulate thousands of genes through canonical modifications 
of histones and non-canonical modification of non-histone regulators of transcription [127,159]. 
Interestingly, in combination, these two compounds revealed a large portion of differentially 
expressed genes that were unique to the combination (~2/3). This was particularly striking in the 
EZH2i-sensitive HMCL FLAM76, which had little to no transcriptomic response from panobinostat 
at the doses used in that experiment. This reveals an interesting area of potential research. As 
discussed in the introduction, epigenetic complexes crosstalk with each-other to form a highly 
complex network of transcriptomic regulation [111,131]. My data suggests that HDACs and EZH2 
cooperate to silence thousands of gene that cannot be upregulated by a loss of either alone. My 
transcriptomic data represents too few HMCLs to make any conclusions regarding whether or not 
there is a consistent GEP that represents genes co-regulated in this manner across HMCLs. It 
would be interesting to perform this transcriptomic analysis in many additional HMCLs to 
determine if such a signature exists.  
Network analysis via IPA revealed a great number of pathways, upstream regulators and 
GO terms enriched in my transcriptomic data. Many of these findings reflected changes that have 
been described in other recent studies that have measured EZH2i-induced transcriptomic 
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changes in lymphoid malignancies and other cancers (referenced in Chapter 3). Many important 
oncogenic pathways were highlighted as well as many other pathways with less obvious 
significance. Unfortunately, the differences and similarities between the two lines were far too 
numerous to derive any specific candidates as factors that distinguish sensitivity. Furthermore, 
the lack of panobinostat single agent response in one of the two HMCLs subjected to 
transcriptomic analysis reduced conclusions that could be drawn regarding mechanisms for 
toxicity in the combination condition.  
The general conclusion from this analysis was that EZH2i upregulates many tumor 
suppressive signaling cascades (e.g. p53 and XAF1) while concomitantly downregulating tumor-
promoting pathways (e.g. MYC and BCL2). These changes are enhanced by the addition of 
HDAC inhibition.  
Interestingly, despite the large number of genes identified to be uniquely modulated in the 
combination condition, relatively few contextually significant pathways, regulators and GO terms 
were uniquely unveiled at the inclusion of panobinostat. This suggests that unlike EZH2i-induced 
GEPs, genes upregulated uniquely in the combination treatment may not represent a specific 
epigenetic program that governs specific pathways but may rather represent non-specific 
upregulation across the genome. This prompted us to consider the possibility that there may be 
an element of non-specific transcriptomic stress produced be the massive induction of 
transcriptomic output. We postulate that it might be possible that, as suggested above, HDAC 
inhibition exacerbates transcriptomic changes in pathways targeted by EZH2 inhibition. These 
changes seem to promote a more apoptotic-permissive state that may sensitize these cells to 
undue transcriptomic stress (over-loading of the transcriptomic machinery). As outlined in 
Chapter 4 gene expression changes observed in the combination condition have an odd 
distribution where genes highly expressed in the untreated condition (baseline) are highly biased 
towards downregulation. This could suggest that undue transcriptomic activation may be 
overloading the transcriptomic machinery and downregulating highly expressed housekeeping 
genes and overexpressed MM-related oncogenes (e.g. MYC). Additional studies are required to 
support the notion of non-specific transcriptomic stress as a mechanism for cytotoxicity in 
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EZH2i/HDACi combination treatment. If this were to be supported empirically, it would present a 
novel cytotoxic mechanism to target (via EZH2 inhibition) malignant plasma cells.  
This study presents a number of future directions, some of which are alluded to above. 
The next logical progression in the pre-clinical evaluation of EZH2i/HDACi combination would be 
to apply this therapeutic strategy in a murine xenograft model of MM. We have discussed this 
prospect with EZH2i-producing companies and have garnered some interest in funding such a 
study. This study revealed several ongoing questions regarding the biological significance of 
EZH2 activity in MM and how EZH2 and HDACs coordinate to regulate large portions of the 
genome. Studies addressing these questions should begin by measuring EZH2/HDAC occupancy 
on chromatin in response to single agent and combination therapy. Some information exists 
regarding complex interactions between these two classes of epigenetic regulators [271,276,277], 
however there is ample room for basic science studies to elucidate the specific molecular and 
contextual basis for these interactions.  
The research presented in this document represents two approaches for overcoming drug 
resistant MM. The first focuses on using HMCL chemosensitivity screening and subsequent 
transcriptomic profiling to identify patients that represent extremes in sensitivity to proteasome 
inhibitors. The second focuses on applying a combination of epigenetic inhibitors to broadly target 
malignant plasma cells even in cases of extreme resistance to proteasome inhibitors. This next 
decade holds great promise for new therapeutic strategies that improve MM management. As we 
continue to combine tumor profiling with efforts to increase our understanding of MM biology, we 
will inch ever closer to defeating this devastating malignancy.  
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